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ABSTRACT 
The work presented in this thesis aims utilizes the versatility of cyanine dyes. Although 
large libraries have generated for these compounds, their remains an unmet need for alternative 
synthetic procedures that both optimizes and allows the dyes to be tailored for the desired use. 
The cyanine dye scaffold contains many points of modification but the central carbon remains a 
point that requires further research. In addition, among the heterocyclic compound that can be 
used in the synthesis of cyanine dyes, the quinoline heterocycle offer interesting optical 
variations to the dyes and can be utilized in the applications that do not require highly fluorescent 
compounds. The dyes presented showcase a superior synthetic procedure, and incorporate the 
quinoline heterocycle in novel compounds.    
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1 INTRODUCTION: A REVIEW OF THE UNIQUE APPLICATIONS OF 
CYANINE DYES 
1.1 PROPERTIES OF CYANINE DYES   
Multiple families of cyanine dyes have been synthesized with various derivatives. NIR 
dyes have raised a great deal of interest due to their versatility in a wide array of applications, low 
energy absorption making for a safer alternative, and modifiability allowing for specific tailoring 
based on the desired application [1-3]. Their absorbance and emission fall outside the range of 
hemoglobin and water, making them ideal for medical applications [4]. Many NIR dyes have been 
screened and libraries have been generated, relating various properties (optical, physiochemical, 
etc.) of the dyes to a specific utility.   
The Near Infrared (NIR) electromagnetic spectrum, is the region between infrared and 
visible light, with a wavelength of 600-900nm [5]. This is a lower energy of the spectrum and has 
opened a new and innovative path for scientific research, raising a great deal of interest in the 
medical field [6]. The low energy light makes for a safer alternative to current imaging techniques, 
while water and endogenous molecules have a low absorbance in this region (fig. 1) allowing for 
distinguishable difference and an enhanced signal to noise (S/N) ratio [6, 7]. The importance of 
this region can only be utilized upon the systematic design and synthesis of probes that have optical 
properties within this NIR wavelength.  
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Figure 1.1.1: Spectra of endogenous molecule absorption [8] 
 
 
Figure 1.1.2: Dermal penetration at a different wavelength of light [9] 
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Among the various NIR probes synthesized, cyanine dyes have shown the greatest use in 
the medical imaging world. Their versatility and tunability allow them to be tailored for specific 
use. From the serendipitous discovery over a century ago to the FDA approval of indocyanine 
green (ICG) cyanine dyes continue to be used in a various application in the medical and industrial 
world [10]. As previously mentioned, ICG was approved by the FDA in 1955 but left room for 
optimization [11]. A myriad of cyanine dyes has been made since, focusing on fluorescent imaging 
and reviews have been written focusing on their use, but the aim of this manuscript is to focus on 
the recent advancements science has made using cyanine dyes and their incorporation to a wider 
array of applications.   
Cyanine dyes are made of a two nitrogen-containing heterocycles linked together by a 
polymethine bridge which allow them to be tunable, modifiable, and versatile [12, 13]. Figure 3 
represents the various points of modifications that can be made. First, the nitrogen-containing 
heterocycle (Fig. 3 blue) can be altered which can affect optical and physical properties. Along 
with the changes made to the heterocycle, varying alkyl groups can be incorporated to the nitrogen 
(Fig. 3 red) of the heterocycle which can alter characteristics such as solubility, the introduction 
of NHS ester for functionalizing and much more [14]. Next, the polymethine chain length can be 
varied (Fig. 3 green), predominately changing the absorbance wavelength by 100 nm per double 
bond which will ultimately change the fluorescence wavelength. The most common dyes used are 
penamethine (5 carbon chain) and heptamethine (7 carbon chain). Along with the changes 
discussed, the central carbon of the polymethine chain can be decorated with various substituents 
(Fig. 3 orange), as well as dyes can be made unsymmetrical by the incorporation of two different 
heterocycles [15-20].             
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Figure 1.1.3: Cyanine dye scaffold 
  
 
To understand cyanine dyes, the quantum and spectral properties have to be understood 
first. An altering of single and double bonds produces a conjugated system that allows for the 
electrons to have a π→π* transition when excited, this transition has a small band gap allowing 
excitation to occur at higher wavelengths [21]. The two nitrogen-containing heterocycle red shifts 
the compound. Upon excitation of the dyes, based on their structure, various relaxation pathways 
may occur, each utilized for a specific use. These relaxation pathways include fluorescence 
emission, vibrational relaxation, and intersystem crossing [22-25].  
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Figure 1.1.4: The Jablonski diagram [26] 
 
 
 
The Jablonski diagram (fig. 4) illustrates the various relaxation pathways that fluorophores 
can take. Absorbance (fig. 4 blue) is a process by which a specific wavelength that excites electrons 
to the singlet excited state. Once excited, a combination of relaxation pathways are taken for the 
electron to return to the energy favorable ground state. Although an excited electron exhibits all of 
these relaxation pathways, we will focus on the dominate relaxation pathway that takes place and 
refer to these dyes as such. Fluorescent dyes use fluorescence (fig. 4 green) as the predominate 
relaxation pathway, these dyes emit light at a longer wavelength upon excitation. The longer 
wavelength is due to the energy lost with the various relaxation which yields a lower energy/longer 
wavelength photon. These dyes are commonly used in various applications in imaging. While, 
some weakly fluorescent dyes observe a greater rate of vibrational, non-radiative, relaxation, as 
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most excited electrons relax back to the ground state via vibrational relaxation. Dyes that 
demonstrate vibrational relaxation as dominate form show a great deal of utility in optoacoustic 
imaging (OAI) [27-37] [38-40], a new and innovative mode of imaging, and photothermal therapy 
(PTT). Other weakly fluorescent dyes, can interact with singlet oxygen, and upon collision, 
observe an electron flip which leads the excited electrons to undergo intersystem crossing (fig.3 
red). Singlet oxygen too observes an electron flip that takes it to the triplet state, accumulation of 
triplet state oxygen, or reactive oxygen species (ROS) [41], is toxic to the cell. This phenomenon 
play a key role in photodynamic therapy (PDT) [42-47]. 
The goal of this review is to highlight key advances in developing cyanine dyes for imaging 
and the new and innovative applications utilizing the other relaxation pathways cyanine dyes can 
take. We aim to highlight unique, current and innovative uses of these dyes as contrast agents, 
optoacoustic imaging agents, photothermal therapy agents, and photodynamic therapy 
photosynthesizes. 
Here in, we will separate the dyes based on their use and relaxation paths. Once again due 
to the vast number of reviews and research done on the more common applications of these dyes, 
the aim is to introduce innovative incorporations of cyanine dyes in a wider array of research 
avenues while still introducing some of the more common utilities.  
1.2 The application of cyanine dyes as fluorescent probes   
The most common use of these dyes remains in fluorescence imaging. Predominantly 
pentamethine and heptamethine dyes are used which emit light in the 700-800 nm range, and upon 
localization in specific organs can be used in image-guided surgery [28, 48-53]. This range is most 
utilized because it solves the direct setbacks that arise from the use of visible light contrast agent 
by avoiding auto-fluorescence and yielding high contrast. Most researchers done in this field 
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predominately uses ICG as a gold standard for fluorescent imaging due to its FDA approval and 
widespread medical usage [11]. Current research aims to alter and optimize the NIR compounds 
by changing the chain length and adding various functional groups to the many points of 
modification of the cyanine dye scaffold. Figure 5 illustrates the use of the dyes in a surgical setting 
for image-guided surgery yielding a great contrast due to the NIR emission of the dyes while 
endogenous tissue fluoresces in the visible range.   
 
 
 
 
Figure 1.1.5: The surgical illustration of image-guided surgery [54] 
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With the modifiability of the cyanine dyes, certain substituents can be incorporated to dye 
scaffold that alters the absorbance, emission and stoke shift. Nagano et. al synthesized a two dye 
system wherein one is pentamethine (A) and the second is heptamethine (B) linked together by a 
cyclohexanediamine linker Figure 7 [55]. A key distinction between pentamethine and 
heptamethine cyanine dyes is the wavelength of the absorbance and fluorescence. Commonly 
pentamethine emission is within the range of heptamethine dye absorbance. Along with the 
differences in optical properties, the two dye used in this study have substantially different 
oxidative potential. Once a linked two dye system is synthesized, quenching occurs making the 
new dye optimal for Förster resonance energy transfer (FRET).  FRET is energy transfer that 
occurs between two absorbing/emitting fluorophores [56-58]. Dyes must be close in proximity so 
that no fluorescence occurs, and contain one fluorophore that emits light which is then absorbed 
by the quencher. These two dyes also have widely different oxidative potential which allows for 
ROS detection. ROS is found in high concentrations in cancerous tissue, which gives these dyes 
medicinal relevancy [55] [59]. 
Upon excitation of pentamethine dye A, quenching occurs by heptamethine dye B. Once 
the two dyes system interacts with ROS, often found diseased (cancerous) area, dye B is cleaved 
due to it's high oxidative potential, and is no longer able to quench dye A, leading an observable 
fluorescent signal. The emitting light will only be found in the area with high ROS concentration, 
such as tumor sites. Although these dyes are not tumor targeting, they can be used for site-specific 
imaging due to the fact that fluorescence will only be observed at cancerous sites with high ROS 
concentrations. This process is illustrated in figure 6. 
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Figure 1.1.6: Representation of FRET and the two dye system [55] 
 
    
 
 
Figure 1.1.7: Dye used in this study [55] 
 
Effective contrast agents must exhibit high contrast and be distinguishable from the 
endogenous tissue. It is ideal that the emission is specific to the target area and observes an increase 
in florescence or “turns-on” upon interaction with the desired target. Focusing on some of the key 
characteristics that differentiate diseased areas versus healthy tissue may enable the intelligent 
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design of the compound for the desired application. Among the vast number of differences, some 
inflamed tissue and tumors have a significantly more acidic environment in comparison to healthy 
tissue. This pH difference offers a condition that can be utilized for imaging [60]. Although 
numerous pH sensitive dyes have been synthesized, few have been in NIR region which offers a 
high contrast in comparison to visible range fluorophores. Additionally, the few NIR pH probes 
have not been used for in vivo applications, which is the future aim of this work.      
Ohe et. al have synthesized ICG derivatives acting as pH probes for in vivo application. 
Incorporating nucleophilic amino-propyl, hydroxyl-propyl, and mercapto-propyl groups allowed 
for on-off fluorescence based on pH [61]. Compound 1C (figure 8) contained a closed ring 
structure of the nitrogen atom of the heterocycle, in physiological conditions the ring structure 
disables emission. Once the nitrogen of the cyclic structure is protonated, going from 1-C to 1-O, 
the ring is opened and the cyanine dye is then fluorescent. Once the series of dyes was screened, 
the optimal dye was chosen for testing and in hopes for future in vivo application in imaging.  
 
 
Figure 1.1.8: Dyes used in this study [61] 
 
The recent advancement in imaging relies heavily on imaging diseased areas at a molecular 
level. Molecular imaging (MI) focuses on imaging at a molecular and cellular level, often utilizing 
ligands and binding sites of proteins.  This mode of targeted imaging allows for more specific 
results and overcomes some of the limitations current imaging moieties have. Among the various 
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diseases, cancer is at the forefront of research due to the vast number of people that get the fatal 
disease. Some statistics show that nearly 1 out 6 deaths are cancer-related. 
Although many chemotherapeutics have been studied, cancer is far from being cured and 
is heavily dependent on surgical resection and early detection for the best possible outcome. 
Studies have shown that early diagnosis can raise the rate of survival by 25% which can be raised 
even higher with full surgical resection [62].   
Though the surgical processes have shown a great deal of advancement in recent years by 
the introduction of new technology into the operating room and advanced surgical procedures have 
been developed, it remains heavily dependent on the surgeon’s experience and expertise. In order 
to better the process and obtain complete resection, contrast agents have been introduced in the 
surgical field. Among many contrast agents, cyanine dyes have been the most studied due to their 
superior properties and various modification sites [13].   
Large libraries have been synthesized and screened for the medical application of cyanine 
dyes, most commonly these dyes localize in specific tissues and are used as contrast agents. While 
a great deal of success has been observed with this technique, another approach entails using more 
specific ligands for known receptors and attaching them to the dye.  
Recent work has been done which synthesized a small library of dyes, tested their optical 
properties and photostability, and followed by attachment of folate to the dyes. Cancer cells have 
shown an overexpression of folate receptors at the surface of the cells. The folate receptor allows 
the dyes to be cancer-specific and can aid in the surgical process. The use of cyanine dyes adds 
greater contrast due to their NIR emission. 
NIR contrast agents have found a great deal of success in the surgical process but are 
limited by the depth of penetration for NIR light. With an approximate 1 cm depth penetration 
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these dyes are unable to be used in noninvasive application [63]. Although more optimal NIR 
contrast agents have been made recently with high quantum yield and molar absorptivity, they 
remain only useful in surgical applications. However, taking advantage of other relaxation 
pathways can broaden the application of theses dyes and open a path for the synthesis of new 
chromophores.  
Excited electrons observe various relaxation pathways but often have a dominant pathway. 
As illustrated in figure 5, laser excitation lead to an electron “jump” into the excited state, which 
for some dyes lead to vibrational relaxation, inducing thermal expansion which propagates an 
acoustic signal detectable by acoustic sensors (ultrasound detector) [24, 39, 40]. The incorporation 
of NIR contrast agents to ultrasound tomography is a new and innovative technique for disease 
imaging and image-guided surgery. With some promising results currently observed, there remains 
an unmet need for the understanding of what constitutes as good agents for OAI.   
1.3 The application of cyanine dyes as optoacoustic contrast agents   
With the many medical advances observed in past decades, among the most important is 
the various novel methods of screening and imaging. Computed tomography (CT), magnetic 
resonance imaging (MRI), positron emission tomography (PET), mammography, and 
ultrasonography are all fairly new imaging methods that have aided in early detection and 
diagnosis of disease, especially cancer. The chance of survival has been proven to be heavily 
reliant on the stage of the disease upon detection and diagnosis [62]. Although these imaging 
modalities have proven to be effective they are limited by their dependence on mass formation 
which might be far too late. Molecular imaging is often referred to as the future of modern 
medicine, allowing cancers and other diseases to be detected long before tumors have been formed. 
Optoacoustic imaging (OAI) has raised a great deal of interest lately, especially upon the 
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introduction of contrast agents. The contrast agent enhances the quality of the image while the 
sensing the acoustic signal increases the depth penetration of the contrast agent significantly. 
The lack of depth penetration is a detrimental set back to NIR fluorescent imaging 
modality, limiting the usefulness of these compounds [63]. Optoacoustic imaging utilizes 
ultrasound detection (fig. 9), allowing for the acoustic signal to be picked up with much greater 
depth versus its fluorescent single. This mode of imaging enables the dyes to be used in a non-
invasive format and applied for non-surgical imaging. Although acoustic signals can be detected 
without the dyes, it lacks the ability to differentiate healthy versus diseased tissue which is made 
possible by the introduction of NIR contrast agents. The incorporation of NIR dyes and 
optoacoustic imaging technology aids in the earlier detection and demonstrates the versatility of 
NIR dyes. Current literature has found some correlation between signal strength and the number 
of rotatable bonds [64]. Other characteristics that enhance the optophore include high molar 
absorptivity and low quantum yield. 
Herein, we attempt to introduce a new and innovative application of NIR contrast agents 
in optoacoustic imaging and provide examples of this application 
 
Figure 1.1.9: Depiction of the optoacoustic imaging [65] 
 
Optoacoustic imaging (OAI) combine photosynthesizers and ultrasound tomography 
providing superior contrast at greater depth. Ultras sound imaging is operational without NIR 
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contrast agents but can be optimized with the introduction of them. With an immense selection of 
contrast agents to choose from, NIR contrast agents show great potential due to their low toxicity 
and the low absorption of endogenous tissue and water in the NIR spectral region. Among NIR 
dyes, cyanine dyes remain the most useful in biological application.      
Although far from optimal due to low molar absorptivity, ICG serves as the gold standard 
for cyanine dyes, often used a representative compound due to its commercial availability and 
FDA approval [11]. Several studies were done using OAI with ICG as the contrast agent in mice 
and found that the NIR contrast agent had a 25% spectral enhancement to spectra observed without 
the incorporation of the dyes, allowing the targeted area to be better observed and with greater 
resolution and contrast [66]. Figure 10 illustrates the enhanced image upon the introduction of 
ICG. Results also indicate that the enhancement was concentration dependent and with varying 
concentration, the signal intensity differed. The study results depict the spectral differences 
observed with varying concentrations. In conclusion, the introduction of ICG allows for greater 
resolution of the OAI image, while OAI allows for greater depth penetration in comparison to the 
NIR dye’s fluorescent signal. This dual benefit shows promising results for the incorporation of 
cyanine dyes into OAI and leaves an unmet need for a synthesis of optimized derivatives for this 
particular and useful application.  
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Figure 1.1.10: Imaging data of OAI upon introduction of ICG [66] 
 
 
What truly determines the optimal contrast agent for OAI remains to be determined as 
various groups aim to correlate key features of different contrast agents versus the resolution of 
the OAI signal. By generating a larger library and further screening a wide array of compounds, 
researchers aim to better understand this new field. 
Upon determination and diagnosis of cancers, determining the extent of metastasis is 
crucial in limiting the disease. Introduction of ICG, adsorbed to gold nanoprobes (AuNR), into the 
lymphatic system, has been shown to allow the tracking of the cancer tissue [67]. ICG along with 
other cyanine dyes are limited by their depth pentation, hence why they have shown success in the 
surgical setting but not as much in pre-surgical imaging. The use of OAI technology enhances the 
depth penetration and is a feasible option for surgical application due to the fact hospitals already 
possess the technology necessary; while AuNR increases the acoustic signal by a factor of 2.3.            
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Figure 1.1.11: In-vivo studies of OAI [67] 
 
 
The ICG was deemed a suitable contrast agent for OAI due to ICG’s efficient signal 
generation and strong absorption in the proper wavelength region (700–1000 nm). The lymph 
vessels of mice affected by cancer were visualized using ICG and OAI technology. The lymph 
vessels were clearly visualized with ICG. These results indicate that an OAI with ICG shows 
promising results in lymph node imaging and cancer tracking for breast cancer metastases. 
The vibrational relaxation and thermal expansion observed in OAI can also be utilized in 
non-imaging methods. Photothermal therapy (PTT) is an innovative therapeutic process that has 
seen some success in treating cancers and other diseases [30, 34, 37]. NIR contrast agents that do 
not use fluorescent or intersystem crossing as the dominate relaxation pathway have been used in 
PTT. NIR laser serves a great deal of purpose due to the high wavelength of light making it both 
safer, due to low energy light, and increase the depth penetration due to the low absorbance of 
endogenous tissue in this region. Among their many advantages, cyanine dyes serve a great 
purpose in this application due to their ability to absorb light in this wavelength. Although high 
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energy radiation is effective on its own, the introduction of NIR contrast agents allows for a more 
optimal process that deters the need for high energy laser. Optimistic results have been observed 
upon the introduction of squaraine cyanine dyes for PTT application and remain to be further 
investigated and optimized [68] [69-71]. 
 
Figure 1.1.12: Photothermal therapy [72] 
 
1.4 The application of cyanine dyes as therapeutic agents   
Cyanine dyes have also shown success in other therapeutic applications. Photodynamic 
therapy (PDT), similar to PTT (fig. 13) in that it uses NIR lasers in killing the diseased cell; 
however, PDT relies excited electrons interacting with singlet oxygen leading to intersystem 
crossing of the dye and triplet oxygen formation which is leads the cells to a apoptotic state [30, 
42-47]. 
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Figure 1.1.13: PDT vs PTT [73] 
 
Photodynamic therapy (PDT) is a cancer treatment method that uses the combination of 
light and photosensitizers to treat the target area. This process works by utilizing organic molecules 
that are non-cytotoxic, creating a safer treatment method. With localized radiation using lower 
energy lights, the treatment method allows for minimal toxicity to the non-diseased area. These 
compounds, in the presence of molecular oxygen, will have no reaction. Once a light source is 
introduced, the compound goes into the singlet excited state, undergoes intersystem crossing to 
the triplet state. The conversation of the photosensitizers to the triplet state transforms triplet 
oxygen into singlet oxygen which produces reactive oxygen species (ROS).  Some ROS includes 
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singlet oxygen, peroxide, and hydroxide, all of which are toxic to cells. This allows for specificity 
through targeted irradiation [15, 46, 69]. Preliminary tests may include the introduction of the 
photosensitizers in the presence of plasmid DNA, then screened for linear and nicked cleavage of 
the strands, both processes leads to cell death.    
Ideal compounds include non- or weakly fluorescent dyes that undergo intersystem 
crossing. Current agents used in PDT, such as porphyrins and psoralen, have a major setback. 
Psoralen absorbs in the UV region allowing them to be used only for topical applications. 
Porphyrins also predominantly absorb in the visible region and also have poor clearance forcing 
the patient to be out of sunlight for long periods of times [15, 46, 69]. Porphyrins are also plighted 
by major synthetic troubles, often having difficult purification methods that include a mixture of 
monomers, dimers, and polymers [74-78]. An alternative was direly needed which lead to the 
investigation of NIR dyes. Among the various NIR dye family, cyanine dyes showed success in 
this application.  
Although ICG has been fairly successful in an imaging application, various other 
heptamethine derivatives have been synthesized for the various application mentioned above. 
Among those derivatives, IR-783 was used in this particular PDT study. Ordinarily quinoline 
pentamethine dyes have shown a great deal of success in PDT assays; however, the introduction 
of a single iodine substituent to the 1,2,3,3-tetramethyl-3H-indol-1-ium salt using the IR-783 
scaffold proved very successful for PDT. The iodine lowered the fluorescent quantum yield 
significantly and showed the most ROS production. Although the symmetric iodine substituted 
IR-783 scaffold (containing an iodine substituents on both salts) showed even lower quantum yield 
it was not as successful in generating ROS, which was concluded using the in vitro studies. Upon 
determining that the optimal dye for PDT was the singly substituted version, in vivo studies were 
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done with BxPC3-Luc mice. Results show that nearly no tumor growth was present for 11 days 
for mice that received the treatment where a 500% growth was observed for those mice that did 
not receive any treatment [79].   
 
 
Figure 1.1.14: Results and dye structure used [79] 
 
 
 
Photodynamic therapy (PDT) has been widely studied in the past decade but is still limited 
by the non-optimal photosynthesizing agents. Often these agents are not water soluble, have low 
molar absorptivity, low ROS generation capabilities, are unconjugatable, and have dark toxicity. 
Large libraries have been screened and found that IR-780 showed promising results. IR-780 is a 
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known mitochondrial targeting agent which is ideal due to the large abundance of oxygen in this 
organelle, negating the issue of hypoxia [80]. IR-780, although somewhat successful, lacks water 
solubility and has unselective dark toxicity [81]. Using the IR-780 scaffold for its mitochondrial 
targeting, while decorating it with different substituents in order to optimize the negative qualities 
allows for synthesis for an ideal PDT agent.  
In order to overcome the water solubility issue, alkylating agents containing pyridine were 
incorporated into the IR-780 scaffold. This enhanced both the water solubility and simultaneously 
the mitochondrial targeting ability. Along with the enhanced physical properties, the charged 
molecule allows for the incorporation hyaluronic acid (HA), a known cancer-specific drug carrying 
ligand. HA is highly selective to CD44 binding sites, which is overexpressed in cancer cells, this 
combines cancer specificity to newly enhanced physical properties of IR-780 dye [82] [83] [84].   
Upon synthesis of the HA-IR-Pyr dye, in vitro and in vivo studies were done to conclude 
if the new substituents added to the IR-780 scaffold proved to be successful for PDT application 
or significantly altered the dye’s properties limiting its effectivity in the application. First cell 
assays were prepared in a competitive study using cancerous cells versus non-cancerous cells, in 
order to determine the selectivity [82] [83].  
Next cancerous cell assays were prepared with HA-IR-Pyr and received irradiation. The 
cells were surveyed using flow cytometry in order to determine the magnitude of apoptosis. Figure 
15 (illustrating the flow cytometry data) indicated that cells with HA-IR-pyr (no laser) had no 
occurrence of apoptosis but after 3 minutes of irradiation a great deal cell death occurred [84] [82]. 
Concluding that the dye complex has negligible dark toxicity and significant toxicity upon 
irradiation. 
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Figure 1.1.15: Flow cytometry results of the study [84] 
     
 
 Following the in vitro study, mouse studies were done, using mice SCC7 cancerous cell 
line. The dye was injected into the mice followed by laser irradiation of the diseased region, and 
the tumors were then resected to observe levels growth suppression. Figure 16 depicts the 
effectivity of irradiation plus HA-IR-Pyr dye in comparison to multiple controls (PBS, light, HA-
IR-Pyr without light) [84]. As illustrated the tumor, in comparison with PBS treated control, saw 
a great deal of shrinkage in with irradiated HA-IR-Pyr, while very limited shrinkage using the dye 
alone (negligible dark toxicity) and with just light alone [84]. Concluding that the modifiability of 
these dyes allows for various incorporation of substituents for optimization allowing for the 
synthesis of the ideal agent for the desired use [84] [83].  
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Figure 1.1.16: In-vivo results of the study [84] 
 
 
1.5 Conclusion 
With the extensive work done with cyanine dyes since their discovery, these dyes continue 
to find utility in innovative fields. Although the predominant research remains focused on the 
introduction of these NIR contrast agents in image-guided surgery, their alternative uses are 
highlighted in this review. These dyes, due to their versatility and numerous points of 
modifications have found success as fluorophores, optaphores, and as therapeutic agents. As their 
research continues to grow these dyes will continue to be optimized for their respective application.   
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2 SYNTHESIS AND OPTICAL PROPERTIES OF NEAR-INFRARED MESO-
PHENYL SUBSTITUTED SYMMETRIC HEPTAMETHINE CYANINE DYES 
Various cyanine dyes have been synthesized and large libraries have been generated; 
however, one point of modification that has not been thoroughly utilized or procedurally 
optimized is the meso carbon (central carbon) of heptamtehine dyes. Previous dyes made 
included a meso-chlorine atom which then substituted, this proved a difficult and inefficient 
procedure. The compounds synthesized in this publication incorporated carbon-based 
substituents which were introduced prior to the synthesis of the dye. This proved a more efficient 
method.  
The introduction of the meso-phenyl substituent was aimed to increase the 
hydrophobicity of heptamethine dyes for human serum albumin (HSA). HSA is the most 
abundant blood protein, containing four hydrophobic binding pockets. This protein plays key 
roles in carrying various compounds throughout the body. The Henary lab previously 
synthesized various cyanine dyes with varying levels of hydrophobicity to further study HSA. 
Among the various dyes, the research did not include heptamethine dye which observes superior 
optical properties. The aim of this project was to enhance the synthetic process of the 
incorporation of carbon bases substituents pre-dye synthesis along with better-understanding 
HSA bonding beyond hydrophobicity.         
This chapter was adapted from the following publication: Synthesis and Optical 
Properties of Near-Infrared meso-Phenyl-Substituted Symmetric Heptamethine Cyanine Dyes. 
Invited manuscript. This article belongs to the Special Issue of Heterocycles. ǂ Co-First authors. 
My contributions to the manuscript consisted of the synthetic, in silico and spectroscopic 
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experiments, analysis, figure and manuscript preparation and frequent discussions concerning the 
project. 
2.1 Abstract 
Heptamethine cyanine dyes are a class of near-infrared fluorescence (NIRF) probes are of 
great interest in bioanalytical and imaging applications due to their modifiability, allowing them 
to be tailored for particular applications. Generally, modifications at the meso-position of these 
dyes are achieved through Suzuki-Miyaura C-C coupling and SRN1 nucleophilic substitution of 
the chlorine atom at the meso-position of the dye. Herein, a series of 15 meso phenyl-substituted 
heptamethine cyanines was synthesized utilizing a modified dianil linker. Their optical 
properties, including molar absorptivity, fluorescence, Stokes shift, and quantum yield were 
measured. The HSA binding affinities of two representative compounds were measured and 
compared to that of a series of trimethine cyanines previously synthesized by our lab. The results 
indicate that the binding of these compounds to HSA is not only dependent on hydrophobicity, 
but may also be dependent on steric interferences in the binding site and structural dynamics of 
the NIRF compounds. 
Keywords: heptamethine cyanine dyes; absorbance; fluorescence; NIRF; physiochemical 
properties; HSA binding 
2.2 Introduction  
Heptamethine cyanine dyes are a class of near infared fluorescence (NIRF) probes that have 
shown great potential in numerous applications due to their versatility, low toxicity, narrow 
absorption band, and high extinction coefficients [8-13]. These dyes are comprised of two terminal 
nitrogen-containing heterocycles linked together by a conjugated polymethine chain. The 
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heterocycles act as both electron donors and acceptors creating an electron deficient system 
throughout the molecule, allowing for long wavelength absorption [14-17]. Heptamethine 
cyanines have been used in medical imaging targeting of: cartilage, bone, endocrine gland, 
biomolecular labeling and much more all serving as contrast agents to aid in surgical application 
[1, 12, 18-23]. Modifications to the cyanine dye scaffold can alter optical properties, solubility, 
and allow for specific tailoring of dyes for their desired application. 
A main contributing factor in the successful application of heptamethine cyanine dyes is their 
modifiability. Most commonly cyanines are modified by the use of different heterocycles and with 
different substituents on the nitrogen atom of the heterocycle. One point of modification that has 
not been thoroughly investigated is the central (meso) carbon of the methine bridge. Many 
derivatives described in literature have been made by replacing the chlorine atom at this position 
via a SRN1 mechanism [12–14]. The most common method of carbon-coupling at the meso-position 
thus far has been done by first synthesizing a heptamethine cyanine dye containing a chlorine atom 
at the meso-position followed by Suzuki-Miyaura coupling [24-26]. While this method is 
successful in synthesizing many scaffolds, it requires tedious purification and the use of an 
expensive palladium catalyst [12–14]. Although the phenyl-substituted dianil linker has been 
previously synthesized, it has not been thoroughly investigated for its effects on the optical 
properties on the NIRF dye [27, 28]. 
Many of these cyanine dyes are administered via IV injection in which the dyes are transported 
to their target through the bloodstream [29]. Human serum albumin (HSA) is the most abundant 
protein in human blood plasma, serving an important role of transporting substances throughout 
the body [29-31]. It is synthesized in the liver and has great binding capacity for hydrophobic 
compounds [29, 32]. HSA has been a widely studied protein because of its importance in drug 
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delivery [15]. HSA contains four binding pockets and does not require biomolecular ligand 
specificity, increasing its versatility and usefulness in medical research [29-32]. It is well described 
in literature that HSA binds to hydrophobic entities. A unique attribute of HSA is that it forms 
reversible covalent bonds with the binding agent, this allows for stable complex formation; 
however, since the bonds are reversible also allows for localization and deposit [33]. 
Our lab has previously designed and synthesized a series of trimethine dyes and studied their 
hydrophobicity and its effect on their interactions with HSA [34]. In this paper, a series of 
heptamethine cyanines with varying degrees of hydrophobicity containing a meso-phenyl 
substituent were synthesized through the use of a phenyl-substituted dianil linker. This method not 
only allows for a more facile synthesis, but a wider array of dyes can be made and can serve for 
various applications. The effect of the phenyl ring on the dyes hydrophobicity, optical properties, 
and binding to HSA was studied and compared to the results from our previous study [34]. 
2.3 Results and Discussion  
2.3.1 Synthesis  
As shown in Scheme 1, the synthesis began with a Fischer indole cyclization by refluxing 4-
substituted phenylhydrazines 1 overnight with 3-methyl-2-butanone in glacial acetic acid. After 
cooling to room temperature, the reaction mixture was neutralized and the substituted indoles 2 
were extracted with dichloromethane to give brown oils. The oils were dissolved in acetonitrile 
and refluxed overnight with various alkyl halides to yield quaternary ammonium salts 3. In parallel 
to salt formation, a phenyl-substituted dianil compound was synthesized through a Vilsmeier 
Haack formylation with 1-phenylcyclohexene (4). The ends of the dianil linker were capped with 
aniline for stability to yield dianil compound 5 [27, 28]. Various quaternary ammonium salts 3 and 
dianil compound 5 are then condensed in a 2:1 ratio in acetic anhydride to yield the final phenyl 
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substituted heptamethine cyanines 6. Pure compounds were obtained in good yield by simply 
washing with methanol. 
The synthetic route described in Scheme 1 provided a new carbon-carbon linked substituent 
position at the meso center adding to the versatility of heptamethine cyanine. The phenyl group 
was added before the dye was made. This allowed for an efficient method of preparation of the 
dye, which required no catalysts or complex purification methods and allowed for a wider array 
hydrophobic compounds to be made. 
Once the dyes have been successfully synthesized, the optical properties were measured, and 
representative dyes 6a and 6k were studied for their binding affinity to HSA. The optical properties 
were compared to commercially available heptamethine dyes Cy-7 and IR-780 due to the similar 
absorbance and emission wavelengths. The binding studies of compounds 6a and 6k were 
compared to MHI-06, a dye previously reported as a strong HSA binding agent [28]. Figure 1 
shows the three dye structures of the standards used in this study.  
 
Scheme 2.1. Synthetic routes of heptamethine dyes containing a phenyl ring at the 
meso-position. 
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Figure 2.1 The structures of the three NIR standards used for the study. 
 
2.3.2 Optical Properties  
As described in Scheme 1, fifteen final NIRF contrast agents were synthesized using the 
dianil linker to yield symmetrical heptamethine cyanines 6a–o. The compounds are broken down 
to three sets of five. Dyes 6a–e all contain a methyl substituent off the nitrogen of the heterocycle 
with varying substitutions at the six position of the heterocyclic ring. 
 
Table 2.1. Spectral Characteristics of dyes Cy-7, IR-780 and 6a–o. All optical properties of the 
dyes were measured in ethanol. 
Dye 
λmax 
(nm) 
λemission 
(nm) 
Stokes 
Shift (nm) 
ε 
(L·mol−1·cm−1) 
Φ 
(%) 
Molecular 
Brightness (M−1· 
cm−1) 
Cy-7 753 775 22 200,000 28 56,000 
IR-
780 
779 799 20 274,000 8.0 20,800 
6a 759 774 15 265,700 31 82,000 
6b 765 780 15 261,000 34 88,700 
6c 767 783 16 275,600 35 96,500 
6d 782 802 20 249,500 10 25,000 
6e 798 810 12 255,400 16 40,900 
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6f 760 781 21 263,900 39 102,300 
6g 769 785 16 286,600 38 109,300 
6h 770 786 16 282,900 42 119,200 
6i 786 804 18 143,500 12 17,200 
6j 797 810 13 231,800 17 39,400 
6k 763 780 17 198,500 45 89,300 
6l 772 787 15 123,400 47 58,000 
6m 773 788 15 239,200 48 113,600 
6n 789 805 16 249,900 11 27,100 
6o 800 812 12 226,600 17 38,500 
 
Dyes 6f–j and 6k–o contain ethyl and butyl N-alkyl substituents, respectively. In comparison 
to Cy-7, the optical properties of the new compounds were found to be superior (Table 1). The 
addition of the cyclohexene ring provided rigidity to the compounds, increasing the molar 
absorptivity and quantum yield by 60,000 M−1·cm−1 and 5%, respectively, for 6a [35]. To 
determine the effects the phenyl ring had on the optical properties, the dyes were compared to IR-
780 [36]. Although the molar absorptivity of the studied dyes were within the same range as the 
commercially available dye, the quantum yield was dramatically increased with the introduction 
of the electron rich phenyl ring, observing a 23–47% increase in quantum yield. The chlorine atom 
at the meso-position of dye IR-780 promotes intersystem crossing due to the heavy atom effect, 
and allows for the molecule to relax in non-radiative means and decreases the fluorescence [37]. 
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Figure 2.2 Absorption spectra of dye 6m in ethanol. 
 
Increasing the length of N-alkyl substituents from a methyl to ethyl did not result in any 
significant changes in optical properties, but an increase in size to the butyl group generally 
lowered the molar absorptivity. Dyes containing hydrogen 6a,f,k, and halogens 6b,c,g,h,l,m at the 
6 position of the heterocycle displayed absorption λmax values of 759–773 nm with redshifts from 
the hydrogen to the halogens from 6 nm to 10 nm which has previously been described [38]. 
Absorption spectra of representative compound 6m was shown in Figure 2. All 15 compounds 
have Stokes shifts ranging from 12 to 21 with the benz[e]indolenine containing compounds 6e,j,o 
having the shortest Stokes shifts. All three methoxy-substituted compounds 6d,i,n had redshifted 
absorption λmax values from 16 nm to 26 nm and lower quantum yields than the other compounds 
while dyes 6e,j,o were redshifted 37–39 nm around 800 nm due to the increased conjugation of 
the benz[e]indolenine heterocycle.  
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
600 650 700 750 800 850 900
A
B
S
Wavelengh (nm)
1µM 1.5µM 2µM 2.5µM 3µM 4µM
37 
 
Figure 2.3 Emission spectra of dye 6m in ethanol with excitation wavelength of 750 nm. 
 
The emission data of all the dyes followed the same trends, whereby compounds containing 
the hydrogen 6a,f,k, and halogen 6b,c,g,h,l,m substituents had the highest quantum yields, and the 
longer N-alkyl chains increased the quantum yield by 4–8% from methyl to ethyl and 5–7% from 
ethyl to butyl. Emission spectra of representative compound 6m was shown in Figure 3. There was 
no significant difference in quantum yield between the hydrogen and halogens within the same 
set. Compounds 6e,j,o containing the benz[e]indolenine heterocycle and 6d,i,n containing the 
methoxy substituent displayed lower quantum yields at 16–17% and 10–12%, respectively, which 
is consistent with previous reports [1]. 
Although molar absorptivity and quantum yield are important properties of fluorophores, in 
regards to application, the molecular brightness gives a more useful indication of the dye utility. 
Molecular brightness takes into account both molar absorptivity and quantum yield [39, 40]. Dyes 
that have high quantum yield, but do not absorb light efficiently (low molar absorptivity) are still 
not emitting as many photons and are less useful for fluorescent applications. N-alkyl substituents 
from a methyl to ethyl increased the molecular brightness by approximately 20,000 M−1·cm−1 for 
the hydrogen- 6a,f,k, and halogen- 6b,c,g,h,l,m substituted compounds while the butyl compounds 
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showed lower molecular brightness. Due to the low quantum yield of the benz[e]indolenine 
heterocycle 6e,j,o and the methoxy 6d,i,n substituted compounds, the two sets showed the lowest 
molecular brightness of 38,000–40,000 M−1·cm−1 and 17,000–20,000 M−1·cm−1, respectively.  
 
2.3.3 Physiochemical Properties  
In our previous study of trimethine cyanine dyes it was shown that MHI-06 (Figure 1) bound 
HSA with an affinity of 1.0 × 106 M−1 [28]. In that study of the binding affinity of trimethine 
cyanines, a trend was observed correlating hydrophobicity to the binding affinity. As the dyes 
became more hydrophobic greater binding affinity was observed. However, the correlation did not 
hold when the large N-phenylpropyl side chain was introduced in the trimethine series [28]. It was 
hypothesized that the binding affinity decreased due to the increased size of the N-phenylpropyl 
side chain hindering the dye from entering the HSA binding pocket. The heptamethine cyanines 
6a–o synthesized in this work were tailored to be hydrophobic in order to observe if binding 
increases due to increase of hydrophobicity or decreases due to the size and steric hindrance. 
 
Table 2.2 Physicochemical properties (in silico) of dyes MHI-06 and 6a–o calculated using 
ChemAxon. The data calculated (at pH 7.4) include: logD, polarizability, dipole moment 
(debye), number of rotatable bonds, volume (Å3), molecular surface area (Å3), and molar mass 
(g/mol). 
Dye 
log
D 
Polarizab
ility 
Dipole 
Moment 
Rot. 
Bonds 
Volu
me 
Molec. Surface 
Area 
Molar 
Mass 
MHI-
06 
4.9
7 
59.45 2.48 8 
441.4
4 
693.216 584.54 
6a 
6.0
7 
65.57 8.35 4 
519.8
5 
814.001 652.66 
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6b 
7.2
8 
69.15 12.3 4 
547.4
5 
845.982 721.55 
6c 
7.6
1 
70.67 13.02 4 
556.1
5 
854.732 810.46 
6d 
5.7
5 
70.51 27.66 6 
569.7
1 
907.778 712.72 
6e 
8.0
5 
80.82 11.87 4 
604.2
7 
936.392 752.78 
6f 
6.7
5 
69.26 3.2 6 
552.1
4 
874.685 680.72 
6g 
7.9
9 
72.84 4.81 6 
579.4
8 
906.491 749.6 
6h 
8.3
2 
74.35 4.97 6 
588.4
7 
915.629 838.51 
6i 
6.4
7 
74.2 25.29 8 
603.8
3 
969.908 740.77 
6j 
8.7
6 
84.51 4.59 6 
638.6
3 
999.272 7803.84 
6k 
8.7
2 
76.65 2.85 10 
620.0
1 
996.744 736.81 
6l 
9.9
2 
80.23 4.63 10 
647.9
1 
1029.597 805.71 
40 
6m 
10.
25 
81.71 4.96 10 
656.6
4 
1038.143 894.62 
6n 
8.4
0 
81.59 26.66 12 
672.6
3 
1094.66 796.88 
6o 
10.
69 
91.9 3.96 10 
708.2
9 
1124.8 836.95 
 
 
The physicochemical properties were calculated using ChemAxon for the 15 heptamethine 
dyes synthesized and compared to our pervious reported compound MHI-06 (Table 2) [28]. 
Physicochemical trends were observed in each series with the same heterocyclic substituents as 
well as with the same N-alkyl side chain. Compounds 6d,i,n with the methoxy substituent showed 
the lowest logD, due to its ability to form hydrogen bonds. Slightly higher values were observed 
for compounds with the hydrogen-substitued 6a,f,k. A 1.2 and 1.5 increase of logD was observed 
from the hydrogen to the chloro-and bromo-substituted compounds, respectively. As expected, the 
series with the benz[e]indolenine heterocycle 6e,j,o had the highest logD values due to the addition 
of another phenyl ring. All heptamethine cyanines 6a–o had significantly higher logD values 
compared to that of MHI-06 due to the presence of the phenyl substituent at the meso-position and 
the increased size of the hydrocarbon skeleton. The dipole moments decreased as the length of the 
alkyl chain increased from methyl to butyl, with methoxy-substituted dyes having significantly 
higher values. In comparison to MHI-06 most of the compounds, especially that of the methyl 
series 6a–e, had a higher dipole moment, but for 6k which had fairly similar results to MHI-06 at 
2.85 and 2.48, respectively. The number of rotatable bonds increased by 2 from methyl to ethyl 
and by 4 from ethyl to butyl. Only the methoxy heterocyclic substitution affected the number of 
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rotatable bonds with an additional rotatable bond for each methoxy in compounds 6d,i,n. MHI-06 
had eight rotatable bonds. All of the dyes with the exception of those containing the methoxy 
substituent had a total polar surface area (TPSA) of 6.25, 0 hydrogen bond donors, and 1 hydrogen 
bond acceptor (ChemAxon). Dyes 6d,i,n containing the methoxy substituent had higher TPSA at 
24.71 and three hydrogen bond acceptors. The presence of the polar oxygen increases the TPSA, 
and increases the number of hydrogen bond that can form by two. 
In summary, the newly synthesized heptamethine dyes 6a–o were significantly more 
hydrophobic then MHI-06, but had a much larger volume. Although hydrophobicity plays a key 
role in binding to HSA, reversibly the size of the compound could inhibit the ability of its binding 
to HSA pocket. Compounds 6a and 6k were tested for their ability to bind to HSA, to further 
determine if other factors than hydrophobicity, play an important role in HSA binding allowing a 
better understanding of binding nature of the larger heptamethine cyanines to HSA. The HSA 
binding spectra for 6a is shown below (Figure 4) and binding data of 6k is shown in the 
supplemental information (6k HSA binding). 
 
Figure 2.4 The emission specra of 6a (0.2 μM) binding with various concentration of 
HSA, in PBS buffer at excitation wavelength of 740 nm. 
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2.3.4 HSA Bidning 
The formation of a dye/substrate conjugate was studied with HSA in phosphate buffered saline 
(PBS), pH 7.4. Previous research by Kim et al. suggested that cyanine dyes bind HSA in with a 
1:1 stoichiometry which was confirmed by our and other research groups using trimethine cyanine 
dyes [10, 34, 41-43]. The binding interactions were studied by measuring the changes in emission 
intensities at a fixed concentration of dye with varying micromolar concentrations of HSA and 
using a double reciprocal plot of [HSA]−1 vs. ΔF−1, where ΔF is the change in emission intensity 
of the Dye/HSA conjugate, that should give a linear relationship. The binding affinity is then 
calculated by dividing the intercept by the slope of the line. Our lab has previously shown that 
both the N-alkyl substituents and the heterocyclic ring of the cyanines have profound effects on 
overall conjugation with the biomolecule [20]. It has also previously been shown that cyanine dyes 
aggregate in polar solvents such as PBS buffer due to strong intermolecular van der Waals 
interactions between the heterocycles that cause the dyes to form H-aggregates [44]. Generally, 
organic solvents are used to disrupt this aggregate formation, but organic solvents cannot be used 
in the presence of HSA due to their ability to denature the biomolecule. Conjugate formation with 
HSA disrupts the aggregation increasing monomer formation and thereby increasing fluorescence 
emission of the dyes. It was determined that heptamethine dye 6a binds HSA with an affinity of 8 
× 101 M−1. This is 5 orders of magnitude lower than the previously tested trimethine cyanines, 
MHI-06, which bound on the order of 1 × 106 M−1 [28]. This further confirms our previous 
hypothesis that the binding affinity of the dyes is not only hydrophobicity dependent, but 
dependent on steric interferences in the HSA binding site. It also confirms that the delocalized 
cationic nature of the dyes may has no electrostatic interference with the binding cavity as this 
heptamethine cyanine displays increased delocalization over the previously tested trimethine 
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cyanines. Albumin is known to bind a variety of compounds including fatty acids, nucleic acids, 
and oligoproteins therefore this information on the steric specificity of these binding sites is of 
potential interest when developing methods to study them [34]. 
2.4 Experimental Section  
2.4.1 General Information  
All chemicals and solvents were of American Chemical Society grade or HPLC purity and 
were used as received. HPLC grade ethanol were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). All other chemicals were purchased from Fisher Scientific (Pittsburgh, PA, USA) or Acros 
Organics (Pittsburgh, PA, USA). The reactions were followed using silica gel 60 F254 thin layer 
chromatography plates (Merck EMD Millipore, Darmstadt, Germany). The 1H-NMR and 13C-
NMR spectra were obtained using high quality Kontes NMR tubes (Kimble Chase, Vineland, NJ, 
USA) rated to 500 MHz and were recorded on an Avance spectrometer (Bruker, Billerica, MA; 
400 MHz for 1H and 100 MHz for 13C) in DMSO-d6, acetone-d6 CD3Cl-d3. High-resolution 
accurate mass spectra (HRMS) were obtained at the Georgia State University Mass Spectrometry 
Facility using a Q-TOF micro (ESI-Q-TOF) mass spectrometer (Waters, Milford, MA, USA). All 
compounds tested were >95% pure. Infrared spectra (FT-IR) were obtained using a Spectrum 100 
spectrometer (PerkinElmer, Duluth, GA, USA) (see Supplementary Materials). UV-Vis/NIR 
absorption spectra were recorded on a Cary 50 spectrophotometer (Varian, Palo Alto, CA, USA) 
interfaced with Cary WinUV Scan Application v3.00 using VWR disposable polystyrene cuvettes 
with a 1 cm pathlength. Laser Induced Fluorescence (LIF) emission spectra were acquired using 
Shimadzu RF-5301 Spectroflurophotometer (Shimadzu Corporation Analytical Instruments 
Division, Duisburg, Germany) interfaced to a PC with RF-5301PC software using Sigma-Aldrich 
disposable polystyrene fluorimeter cuvettes with a 1 cm pathlength. All spectral measurements 
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were recorded at room temperature. The data analysis and calculations were carried out using 
Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). 
2.4.2 Synthetic Procedure  
A solution of POCl3 (11 mL, 117.66 mmol) in dichloromethane (10 mL) was added 
dropwise to a solution of DMF (13 mL, 167.89 mmol) in dichloromethane (13 mL) at 0 °C for 
30 min under inert conditions. Then 1-phenylcyclohexene (4, 5.5 mL, 32.81 mmol) was 
dissolved in dry dichloromethane (5 mL) and added dropwise to the solution which was then 
refluxed for 3 h. The solution was allowed to cool to room temperature and then poured over 500 
mL of ice/water. Aniline (9 mL, 98.57 mmol) in ethanol (9 mL) was added to cap the ends. The 
crude solid was collected and washed with diethyl ether and hexanes. Resulting in the dianil 
linker 5 as a pure compound and used without further purification. 
In parallel, substituted hydrazines 1 (4.0 g, 22.25 mmol) were reacted with 3-
methylbutanone (3 mL, 28.04 mmol) in acetic acid and heated to a 100 °C for 24 h. The solution 
was then neutralized using sodium bicarbonate and extracted using dichloromethane; affording 
substituted indolenine heterocycles 2 which was dried under reduced pressure. The heterocycles 
2 were then reacted with an alkyl halide in acetonitrile at 100 °C for 12–18 h. The quaternary 
ammonium salts 3 were precipitated with diethyl ether, and collected.  
The various salts 3 (2 molar eq), the dianil linker 5 (1 molar eq), and sodium acetate (2 
molar eq) were dissolved in acetic anhydride and heated to 60 °C for 2–3 h. The crude product 
was then precipitated with diethyl ether, collected, and washed with methanol to yield 
heptamethine dyes 6 as pure sample. 
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2.4.3 Characterization 
1,3,3-Trimethyl-2-((E)-2-((E)-6-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)-3,4,5,6-
tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-3H-indol-1-ium iodide, 6a: Yield 77%; m.p. > 260 °C; 1H-
NMR (CDCl3) δ 1.11 (s, 12H), 1.95 (m, 2H), 2.68 (t, J = 6.0 Hz, 4H), 3.58 (s, 6H), 6.17 (d, J = 
14.0 Hz, 2H), 7.16 (m, 4H), 7.25 (d, J = 8.4 Hz, 2H), 7.34 (m, 4H), 7.46 (d, J = 7.6 Hz, 2H), 7.62 
(m, 3H). 13C-NMR (CDCl3) δ 21.3, 24.5, 27.3, 31.5, 48.5, 100.7, 111.3, 122.7, 124.9, 128.5, 128.8, 
129.0, 129.6, 131.0, 139.1, 140.9, 143.3, 147.3, 161.5, 172.1. HRMS (ESI) m/z: calcd. for 
C38H41N2
+ 525.3264, obsd 525.3241. 
5-Chloro-2-((E)-2-((E)-6-(2-((E)-5-chloro-1,3,3-trimethylindolin-2-ylidene)ethylidene)-3,4,5,6-
tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 6b: Yield 78%; 
m.p. > 260 °C; 1H-NMR (CDCl3) δ 1.17 (s, 12H), 2.07 (m, 2H), 2.74 (t, J = 6.4 Hz, 4H), 3.65 (s, 
6H), 6.12 (d, J = 14.0 Hz, 2H), 7.05 (d, J = 8.4 Hz, 2H), 7.17 (m, 6H), 7.30 (t, J = 8.4 Hz, 2H), 
7.56 (m, 3H); 13C-NMR (CDCl3) δ 21.1, 25.0, 27.5, 32.5, 48.5, 100.8, 111.3, 122.5, 128.2, 128.5, 
128.7, 129.4, 130.2, 133.0, 138.7, 141.5, 142.1, 148.2, 163.0, 171.4. HRMS (ESI) m/z: calcd. for 
C38H39Cl2N2
+ 593.2485, obsd 593.2475. 
5-Bromo-2-((E)-2-((E)-6-(2-((E)-5-bromo-1,3,3-trimethylindolin-2-ylidene)ethylidene)-3,4,5,6-
tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 6c: Yield 75%; m.p. 
> 260 °C; 1H-NMR (CDCl3) δ 1.12 (s, 12H), 2.08 (m, 2H), 2.76 (t, J = 6.4 Hz, 4H), 3.66 (s, 6H), 
6.15 (d, J = 14.0 Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H), 7.15 (d, J = 14.0 Hz, 2H), 7.21 (dd, J = 7.6 
Hz, 2H), 7.46 (dd, J = 8.4 Hz, 2H), 7.56 (m, 3H). 13C-NMR (CDCl3) δ 21.0, 25.0, 27.5, 32.5, 48.4, 
100.9, 111.7, 117.7, 125.3, 128.2, 128.5, 129.4, 131.5, 133.2, 138.7, 142.0, 142.4, 148.1, 162.9, 
171.2. HRMS (ESI) m/z: calcd. for C38H39Br2N2
+ 681.1475, obsd 681.1475. 
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5-Methoxy-2-((E)-2-((E)-6-(2-((E)-5-methoxy-1,3,3-trimethylindolin-2-ylidene)ethylidene)-
3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-1,3,3-trimethyl-3H-indol-1-ium iodide, 6d: Yield 
73%; m.p. 238–240 °C; 1H-NMR (CDCl3) δ 1.17 (s, 12H), 2.06 (m, 2H), 2.70 (t, J = 6.4 Hz, 4H), 
3.61 (s, 6H), 3.82 (s, 6H), 6.03 (d, J = 14.0 Hz, 2H), 6.76 (s, 2H), 6.86 (d, J = 8.8 Hz, 2H), 7.04 
(d, J = 8.4 Hz, 2H), 7.10 (d, J = 14.0 Hz, 2H), 7.21 (d, J = 6.8 Hz, 2H), 7.55 (m, 3H); 13C-NMR 
(CDCl3) δ 21.2, 24.9, 27.5, 32.2, 48.5, 55.9, 99.8, 109.1, 110.9, 112.8, 128.0, 128.4, 129.5, 131.4, 
136.5, 139.1, 142.2, 146.8, 157.8, 161.3, 171.0. HRMS (ESI) m/z: calcd. for C40H75N2O2
+ 
585.3476, obsd 585.3469. 
1,1,3-Trimethyl-2-((E)-2-((E)-6-((E)-2-(1,1,3-trimethyl-1,3-dihydro-2H-benzo[e]indol-2-
ylidene)ethylidene)-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-1H-benzo[e]indol-3-ium 
iodide, 6e: Yield 63%; m.p. > 260 °C; 1H-NMR (CDCl3) δ 1.50 (s, 12H), 2.11 (m, 2H), 2.79 (t, J 
= 6.4 Hz, 4H), 3.77 (s, 6H), 6.16 (d, J = 14.0 Hz, 2H), 7.30 (m, 2H), 7.44 (m, 4H), 7.55 (t, J = 7.6 
Hz, 2H), 7.66 (m, 3H), 7.92 (m, 6H); 13C-NMR (CDCl3) δ 21.2, 25.0, 27.1, 32.5, 50.2, 99.9, 110.5, 
121.9, 124.7, 127.5, 128.0, 128.3, 128.6, 129.5, 130.1, 130.5, 131.7, 132.2, 132.9, 139.0, 140.2, 
147.1, 162.0, 173.3. HRMS (ESI) m/z: calcd. for C46H45N2
+ 625.3577, obsd 625.3570. 
1-Ethyl-2-((E)-2-((E)-6-(2-((E)-1-ethyl-3,3-dimethylindolin-2-ylidene)ethylidene)-3,4,5,6-
tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-3,3-dimethyl-3H-indol-1-ium iodide, 6f; Yield: 70%; m.p. 
> 260 °C; 1H-NMR (acetone-d6) δ 1.11 (s, 12H), 1.24 (t, J = 7.2 Hz, 6H), 1.96 (m, 2H), 2.97 (t, 
4H), 4.14 ( m, 4H) 6.20 (d, J = 14 Hz, 2H), 7.18 (m, 4H), 7.35 (m, 4H), 7.47 (d, J = 7.6 Hz, 2H), 
7.61 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 12.3, 21.2, 25.0, 27.6, 39.7, 48.6, 99.8, 110.2, 122.1, 
124.8, 128.2, 128.6, 128.7, 129.5, 132.2, 138.9, 140.8, 141.9, 148.2, 162.6, 170.9; 13C-NMR 
(acetone-d6) δ 12.5, 21.3, 24.6, 27.4, 39.8, 40.0, 40.2, 48.7, 100.2, 111.2, 123.0, 125.0, 128.6, 
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129.0, 129.1, 129.6, 131.1, 141.1, 142.1, 147.7, 171.2. HRMS (ESI) m/z: calcd. for C40H45N2
+ 
553.3577, obsd 553.1566. 
5-Chloro-2-((E)-2-((E)-6-(2-((E)-5-chloro-1-ethyl-3,3-dimethylindolin-2-ylidene)ethylidene)-
3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-1-ethyl-3,3-dimethyl-3H-indol-1-ium iodide, 6g; 
Yield 64%; m.p. > 260 °C; 1H-NMR (CDCl3) δ 1.16 (s, 12H), 1.38 (t, J = 7.2 Hz, 6H), 2.07 (t, J 
= 5.6, 2H), 2.73 (t, J = 6.0 Hz, 4H), 4.142 (m, 4H), 6.10 (d, J = 14.0 Hz, 2H), 7.07 (d, J = 8.4 Hz, 
2H), 7.28 (m, 8H) 7.59 (m, 3H); 13C-NMR (CDCl3) δ 12.2, 21.1, 25.0, 27.5, 40.7, 48.6, 100.1, 
111.4, 122.6, 128.3, 128.7, 128.8, 129.4, 130.3, 132.6, 138.7, 140.5, 142.4, 148.3, 163.1, 170.5. 
HRMS (ESI) m/z: calcd. for C40H43Cl2N2
+ 621.2798, obsd 621.2788. 
5-Bromo-2-((E)-2-((E)-6-(2-((E)-5-chloro-1-ethyl-3,3-dimethylindolin-2-ylidene)ethylidene)-
3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-1-ethyl-3,3-dimethyl-3H-indol-1-ium iodide, 6h; 
Yield 71%; m.p. > 260 °C; 1H-NMR (CDCl3) δ 1.18 (s, 12H), 1.41 (t, J = 7.2 Hz, 6H), 2.10 (t, J 
= 6.4 Hz, 2H), 2.75 (t, 5.6 Hz, 4H), 4.16 (m, 4H), 6.13 (d, J = 14.4 Hz, 2H), 7.22 (m, 10H), 7.59 
(m, 3H); 13C-NMR (CDCl3) δ 12.2, 21.1, 25.1, 27.5, 40.1, 48.6, 100.3, 111.7, 117.7, 125.5, 128.3, 
128.6, 129.4, 131.6, 133.0, 138.8, 141.0, 142.7, 148.2, 162.9, 170.3. HRMS (ESI) m/z: calcd. for 
C40H43Br2N2
+ 709.1788, obsd 709.1780. 
1-Ethyl-2-((E)-2-((E)-6-(2-((E)-1-ethyl-5-methoxy-3,3-dimethylindolin-2-ylidene)ethylidene)-
3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-5-methoxy-3,3-dimethyl-3H-indol-1-iumiodide, 6i; 
Yield 61%; m.p. > 260 °C; 1H-NMR (acetone-d6) δ 1.22 (s; 12H), 1.34 (t, J = 7.2 Hz, 6H), 2.02 
(m, 2H), 2.73 (t, J = 6.0 Hz 4H), 3.84 (s, 6H), 4.21 (m, 4H), 6.23 (d, J = 14 Hz 2H), 6.23 (d, J = 
2.8 Hz 2H) 6.94 (d, J = 2.4 Hz 2H) 7.22 (s, 2H) 7.28 (m, 6H) 7.66 (m, 3H); 13C-NMR (acetone-
d6) δ 11.6, 21.3 24.5, 26.8, 39.0, 48.8, 55.4, 99.1, 109.0, 111.2, 113.4, 128.0, 128.7, 129.5, 130.3, 
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135.5, 139.4, 142.8, 145.0, 158.1, 161.0, 170.6. HRMS (ESI) m/z: calcd. for C42H49N2O2
+ 
613.3789, obsd 613.3777. 
3-Ethyl-2-((E)-2-((E)-6-((E)-2-(3-ethyl-1,1-dimethyl-1,3-dihydro-2H-benzo[e]indol-2-
ylidene)ethylidene)-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-1,1-dimethyl-1H-
benzo[e]indol-3-ium iodide, 6j; Yield 65%; m.p. > 260 °C; 1H-NMR (CDCl3) δ 1.46 (t, J = 6.8 
Hz, 6H), 1.51 (s, 12H), 2.13 (t, J = 5.6 Hz, 2H), 2.79 (t, J = 6.0 Hz, 4H), 4.28 (m, 4H), 6.17 (d, J 
= 14.0 Hz, 2H), 7.45 (m, 13H), 7.94 (m, 6H); 13C-NMR (CDCl3) δ 99.3, 110.4, 122.0, 124.8, 
127.6, 128.1, 128.3, 128.7, 129.5, 130.1, 130.7, 131.7, 132.0, 133.3, 139.1, 139.3, 147.3, 162.0, 
172.4. HRMS (ESI) m/z: calcd. for C48H49Cl2N2
+ 593.2485, obsd 593.2475. 
1,3,3-Trimethyl-2-((E)-2-((E)-6-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)-3,4,5,6-
tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-3H-indol-1-ium iodide, 6k; yield 68%; m.p. > 260 °C; 1H-
NMR (CDCl3) δ 1.04 (t, J = 7.2 Hz, 6H), 1.23 (s, 12H), 1.49 (m, 4H), 1.80 (m, 4H), 2.11 (t, J = 
6.0 Hz, 2H), 2.745 (s, 4H), 4.04 (t, J = 7.2 Hz, 4H), 6.10 (d, J = 14 Hz, 2H), 7.07 (d, J = 11.6 Hz, 
2H), 7.22 (m, 6H), 7.33 (t, J = 7.2 Hz, 2H), 7.61 (m, 3H)); 13C-NMR (CDCl3) 14.0, 20.5, 21.3,25.0, 
27.7, 29.4, 110.4, 122.1, 124.8, 128.2, 128.6, 129.6, 140.8, 142.3. HRMS (ESI) m/z: calcd. for 
C44H53N2
+ 609.4203, obsd 609.4198. 
1-Butyl-2-((E)-2-((E)-6-(2-((E)-1-butyl-5-chloro-3,3-dimethylindolin-2-ylidene)ethylidene)-
3,4,5,6-tetra-hydro-[1,1′-biphenyl]-2-yl)vinyl)-5-chloro-3,3-dimethyl-3H-indol-1-ium iodide, 6l: 
Yield 67%; m.p. > 260; 1H-NMR (CDCl3) δ 1.03 (t, J =7.2 Hz, 6H), 1.191 (s, 12H), 1.47 (m, 4H), 
1.78 (t, J = 6.8 Hz, 4H), 2.12 (s, 2H), 2.75 (s, 4H), 4.02 (s, 4H), 6.09 (d, J = 12.4 Hz, 2H), 6.98 
(d, J = 8.0 Hz, 2H), 7.28 (m, 8H), 7.86 (m, 3H); 13C-NMR (CDCl3) δ 14.0, 20.4, 21.3, 25.0, 27.7, 
29.3, 44.7, 48.6, 100.4, 111.3, 122.7, 128.3, 128.6, 129.6, 130.2, 138.7, 141.0, 142.4, 148.5, 171.0. 
HRMS (ESI) m/z: calcd. for C44H51Cl2N2
+ 677.3424, obsd 677.3421. 
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1-Butyl-2-((E)-2-((E)-6-(2-((E)-1-butyl-3,3-dimethylindolin-2-ylidene)ethylidene)-3,4,5,6-
tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-3,3-dimethyl-3H-indol-1-ium iodide, 6m: Yield 65%; m.p. 
> 260 °C; 1H-NMR (CDCl3), δ 1.04 (t, J =7.2 Hz, 6H), 1.20 (s, 12H), 1.51 (m, 4H), 1.81 (m, 4H), 
2.13 (t, J = 5.2 Hz, 2H), 2.75 (s, 4H), 4.04 (t, J =7.2 Hz, 4H), 6.10 (d, J = 14.0 Hz, 2H), 7.07 (d, 
J = 8 Hz, 2H), 7.20 (m, 8H), 7.61 (m, 3H); 13C-NMR (CDCl3) δ 14.0, 20.5, 21.3, 25.0, 27.7, 29.4, 
44.4, 48.6, 100.0, 110.3, 122.1, 124.7, 128.2, 128.6, 129.6, 132.1, 138.8, 140.8, 142.3, 148.4, 
162.9, 171.4. HRMS (ESI) m/z: calcd. for C44H51Br2N2
+ 765.2414, obsd 765.2422. 
1-Butyl-2-((E)-2-((E)-6-(2-((E)-1-butyl-5-methoxy-3,3-dimethylindolin-2-ylidene)ethylidene)-
3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-5-methoxy-3,3-dimethyl-3H-indol-1-ium iodide, 
6n: Yield 66%; m.p. > 260 °C; 1H-NMR (CDCl3) δ 1.01 (t, J = 6.8 Hz, 6H), 1.17 (s,12H), 1.46 
(m, 4H), 1.80 (m, 4H), 2.07 (s, 2H), 2.68 (s, 4H), 3.82 (s, 6H), 4.03 (t, J = 7.2 Hz, 4H), 6.00 (d, J 
= 14.0 Hz, 2H) 6.78 (s, 2H), 6.88 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 8.8 Hz, 2H), 7.11 (d, J = 14.0 
Hz, 2H), 7.21 (d, J = 6.8 Hz, 2H), 7.57 (m, 3H); 13C-NMR (CDCl3) δ 13.9, 20.4, 21.3, 24.8, 27.7, 
29.4, 44.6, 48.7, 56.0, 99.4, 109.1, 111.1, 113.1, 128.1, 128.6, 129.4, 130.9, 135.9, 139.0, 142.4, 
146.9, 157.9, 161.4, 170.6. HRMS (ESI) m/z: calcd. for C46H57N2O2
+ 669.4415, obsd 669.4404. 
3-Butyl-2-((E)-2-((E)-6-((E)-2-(3-butyl-1,1-dimethyl-1,3-dihydro-2H-benzo[e]indol-2-
ylidene)ethylidene)-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)vinyl)-1,1-dimethyl-1H-
benzo[e]indol-3-ium iodide, 6o: Yield 70%; m.p. >260 °C; 1H-NMR (CDCl3) δ 1.03 (t, J = 7.2 
Hz, 6H), 1.52 (m, 16H), 1.86 (m, 4H), 2.16 (t, J = 6.0 Hz, 2H), 2.79 (s, 4H), 4.17 (s, 4H), 6.15 (d, 
J = 14.4 Hz, 2H), 7.34 (m, 6H), 7.45 (d, J = 7.6 Hz, 2H), 7.53 (m, 2H), 7.68 (t, J = 2.8 Hz, 3H), 
7.93 (m, 6H); 13C-NMR (CDCl3) δ 14.0, 20.4, 21.4, 25.0, 27.2, 29.7, 44.6, 50.4, 99.6, 110.6, 122.0, 
124.8, 127.6, 128.1, 128.4, 128.7, 129.6, 130.1, 130.6, 131.7, 133.2, 139.0, 139.7, 147.3, 172.8. 
HRMS (ESI) m/z: calcd. for C52H57N2
+ 709.4516, obsd 709.4540. 
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2.4.4 Stock Solution  
Stock solutions of the dyes and standard were prepared by weighing the solid on a 5-digit 
analytical balance in an amber vial and adding solvent via a class A volumetric pipette to a final 
concentration of 1.0 mM. The vials were vortexed for 20 s and then sonicated for 15 min to ensure 
complete dissolution. The stock solutions were stored in a dark freezer at 4 °C when not in use. 
Working solutions were prepared just prior to use by dilution of the stock to final concentrations. 
 
2.4.5 Method of Determining Molar Absorptivity and Fluorescence Quantum Yield 
Stock solutions were used to prepare six dilutions of dyes in ethanol and the standard with 
concentrations ranging from 1 μM to 4 μM using a class A volumetric pipette in order to maintain 
absorption between 0.1 and 1.0. The dye solutions were diluted ten-fold for fluorescence in order 
to minimize inner filter effect. The absorbance spectra of each sample was measured in triplicate 
from 400nm to 900 nm. The emission spectrum of each sample was measured in triplicate with a 
750 nm excitation wavelength.  
For molar absorptivity, the absorbance at the wavelength of maximum absorbance (λmax) was 
determined and the absorbance of each sample at λmax was plotted as a function of dye 
concentration. The linear regression equation was computed using Microsoft Excel. 
The fluorescence quantum yields were determined relative to the indocyanine green standard 
utilizing the gradient from the plot of integrated fluorescence intensity vs. absorbance (Grad) and 
the published quantum yield of the standard (φS, 13.2% [35]) as per Equation (1): 
φD = φS * GradD/GradS * η
2
S/η
2
D (1) 
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2.4.6 HSA Binding Study  
A stock solution of 6a (4 × 10−5 M) and HSA (4 × 10−5 M; Sigma Aldrich, St. Louis, MO, 
USA) were prepared in PBS buffer. Fluorescence titration with HSA concentrations (0–2 μM) 
were made by mixing 35 μL dye solution with PBS buffer solution with and without HSA to a 
total volume of 4000 μL in a fluorescence cuvette to make working solutions of 2 μM dye. 
Fluorescence spectra were measured in duplicate with excitation at 740 nm and slit widths of 5 nm 
for both excitation and emission. 
2.5 Conclusion  
A series of 15 phenyl-substituted heptamethine cyanines was synthesized in good yields and 
characterized by 1H- and 13C-NMR. Their optical properties including molar absorptivity, 
fluorescence, Stokes shift, and quantum yield were measured. The optical properties followed 
similar trends to previously published cyanine dye MHI-06. The binding affinity of one of these 
heptamethine cyanine dyes to HSA was measured to be 5 orders of magnitude lower than our 
previous synthesized trimethine cyanines further confirming the hypothesis that the binding affinity 
of the dyes is not only hydrophobicity dependent, but dependent on steric interferences in the binding 
site [34]. Because albumin is known to bind a variety of compounds, this information on the steric 
specificity of these binding sites is of potential interest when developing methods to study them.  
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3 THE INCORPORATION OF THE QUINOLINE HETEROCYCLE TO 
PENTAMETHINE AND HEPTAMETHINE CYANINE DYES  
3.1 Introduction 
Photodynamic therapy (PDT), as introduced earlier, has raised a great deal of interest as a 
new and innovative method for treating cancers and other skin diseases. The current PTD 
methods have shown some success but have left room for improvement. Through the work done 
by Dr. Grant and other research groups, it has been determined that cyanine dyes are strong 
candidates in this field. Cyanine dyes act as a contrast agent that induces apoptosis via reactive 
oxygen species (ROS) generation [1-4]. Although some dyes have shown effective DNA 
cleavage in preliminary studies there is much room for optimization and the need for large 
library generation.  
Recent work by the Henary and Grant lab have shown that quinoline-based pentamethine 
dyes are effective for PDT application [5]. The main compounds that proved effective were 4-
methyl quinoline-based pentamethine cyanine dyes and bromine substituted 2-methyl 
pentamethine cyanine dyes. Due to the effectivity of these compounds, it initiated a great deal of 
interest to further develop these two compound via the introduction of different substituents.  
The 2-methyl quinoline heterocycle enables a great deal optimization due to the fact it 
halogen substituents can be incorporated onto the heterocycle. Since the bromine atom at the 6-
position proved effective in previous work, fluorine was introduced into the heterocycle due to 
the lipophilicity, electronegativity, and small size of the fluorine atom [6]. Along with chemical 
and physical characteristics of the fluorine atom, it has shown great success upon to its 
introduction in various other medical application. With the reasons presented, a project was 
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generated in aims to study the effects of fluorine on the quinoline heterocycle in PDT 
application.  
Although the substituents have proven to be effective at altering the results, the counter-
ion can play a vital role in prolonging the triplet state, ultimately making the contrast agent more 
effective. A relatively common counter-ion for cyanine dyes is the iodine atom, which is a triplet 
state quencher [7]. The iodine atom is introduced into the dye upon alkylation of heterocycle 
during the salt synthesis.  In order to study the effects of the counter-ion, different alkylating 
agents and methods were used to study the effects iodine versus other counter-ions to determine 
the effects the counter ion has on the effectivity of the contrast agent in PDT application.  
The quinoline heterocycle yield dyes that are non-fluorescent, it allows the dyes to be 
used for other application. Due to its structure of the heterocycle, a second double bond 
contributes to the conjugation, this extra double bond, in comparison the 2,3,3-trimethyl-3H-
indole heterocycle, enable the heterocycle to extend the conjugation red-shifting the compounds 
50 nm, and 100 nm in the 2-methyl based quinoline cyanine dyes and 4-methyl quinoline 
cyanine dyes; respectively. Many pentamethine dyes have been made using these dyes; however, 
the introduction of these heterocycles to heptamethine cyanine dyes is new. The benefits of 
synthesizing quinoline-based heptamethine dyes are the far red-shift that is observed pushing 
these dyes to the near-infrared II window (1000 nm-1700 nm) range. These dyes offer a great 
contrast with respect to endogenous tissue in a biological application and unveil a largely 
untapped field in the cyanine dye field. These compounds can be used for various application 
and offer a great deal variance due to the many the points of modifications they provide. 
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3.3 Experimental Section 
3.3.1 Materials  
All chemicals and solvents were of American Chemical Society grade or HPLC purity and 
were used as received. HPLC grade ethanol was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). All other chemicals were purchased from Fisher Scientific (Pittsburgh, PA, USA) or Acros 
Organics (Pittsburgh, PA, USA). The reactions were followed using silica gel 60 F254 thin layer 
chromatography plates (Merck EMD Millipore, Darmstadt, Germany). The 1H-NMR and 13C-
NMR spectra were obtained using high-quality Kontes NMR tubes (Kimble Chase, Vineland, NJ, 
USA) rated to 500 MHz and were recorded on an Avance spectrometer (Bruker, Billerica, MA; 
400 MHz for 1H and 100 MHz for 13C) in DMSO-d6, acetone-d6 CD3Cl-d3. High-resolution 
accurate mass spectra (HRMS) were obtained at the Georgia State University Mass Spectrometry 
Facility using a Q-TOF micro (ESI-Q-TOF) mass spectrometer (Waters, Milford, MA, USA). All 
compounds tested were >95% pure. Infrared spectra (FT-IR) were obtained using a Spectrum 100 
spectrometer (PerkinElmer, Duluth, GA, USA) (see Supplementary Materials). UV-Vis/NIR 
absorption spectra were recorded on a Cary 50 spectrophotometer (Varian, Palo Alto, CA, USA) 
interfaced with Cary WinUV Scan Application v3.00 using VWR disposable polystyrene cuvettes 
with a 1 cm pathlength.. All spectral measurements were recorded at room temperature. The data 
analysis and calculations were carried out using Microsoft Excel (Microsoft Corporation, 
Redmond, WA, USA). 
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3.3.2 Scheme of the pentamethine fluorinated quinoline-based cyanine dyes 
 
 
3.3.3 The synthesis of the pentamethine fluorinated quinoline-based cyanine dyes 
Linkers (9a-b) were prepared following the procedure published by the Henary lab [].  A 
solution of a 2.5 molar equivalence of aniline (7) dissolved in ethanol was added dropwise to a 1 
molar equivalence of 2,3-dichloro-4-oxo-but-2-enoic acid dissolved in ethanol solution. The 
mixture was heated for 5 h at 60 °C. The reaction was monitored using a reverse phase thin layer 
chromatography (TLC) (mobile phase: DCM), upon completion of the reaction, the mixture was 
poured into an excess of ethyl ether and. The precipitate was vacuum filter and dried under 
reduced pressure. A golden precipitate was assumed pure and used without further purification.   
Linkers (11a-c) were prepared by reacting a solution of DMF dissolved in DCM, POCl3 
was then added dropwise at 0 °C. Substituted benzoic acid was then added dropwise and the 
reaction was refluxed for 4 h. The reaction was monitored using TLC (mobile phase: Ethyl 
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acetate/hexanes). The solution was allowed to cool and poured over ice. Lithium hydroxide was 
added, precipitating the product. The solid was vacuumed filtered, allowed dry overnight and 
used without further purification.     
The synthesis of the fluorinated quinoline salt was prepared with respect to how many 
other heterocyclic salts. The 6-fluoro quinoline heterocycle (12) was purchased and used without 
further purification. A 1 molar equivalence of the fluorinated heterocycle and an excess of 
methyl iodide was dissolved in acetonitrile and heated to 100 °C in a sealed tube for 12 h. The 
reaction was allowed to cool, poured over chilled ethyl ether and vacuum filtered. A yellow 
precipitate (13) was afforded and used without further purification.  
The synthesis of the dyes (14a-c and 15a-c) were attempted using conventional heat 
which resulted in no reaction. Next, the reaction was done using microwave radiation.  A 2 molar 
equivalence of the fluorinated heterocyclic salt (13), a 2 molar equivalence of triethylamine 
(TEA), and a 1 molar equivalence of linkers (9a-c, 11a-c) were reacted in a microwave reactor 
(100 °C, 115 W, 5 min). The reaction was monitored using UV-Vis spectroscopy. The reaction 
mixture was precipitated using ethyl ether and vacuum filtered. The crude product was 
recrystallized in ethanol and filtered again yielding dyes (14a-c, 15a-c). 
 
3.3.4 Scheme of the pentamethine quinoline-based cyanine dyes with varying counter-ions 
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3.3.5 The synthesis of the pentamethine quinoline-based cyanine dyes with varying counter-
ions 
The 2-methyl quinoline (16) heterocycle was methyl alkylated using four different 
synthetic procedures to obtain varying counter-ions. In a 1:1 molar equivalence the heterocycle 
was reacted with methyl iodide, methyl 4-methylbenzenesulfonate, and dimethyl sulfoxide. The 
reaction was done using acetonitrile as solvent and heated to 100 °C for 12-24 h. Upon 
completion, ethyl ether was added to the reaction mixture yielding 1,2-dimethyl quinoline 
heterocyclic salts 17a-c and assumed pure with no further purification. In a 2:1:2 molar 
equivalence, salts 17a-c,  linker 9b, and trimethylamine were dissolved in acetic anhydride and 
heated to 80 °C for 1 h. The reaction was monitored using UV-Vis spectroscopy, and upon 
completion was allowed to cool to room temperature and poured into an excess amount of ethyl 
ether. The crude precipitate was collected by vacuum filtration and recrystallized, affording pure 
product 19a-c. In order to obtain compound 19d, salt 17a was deprotonated in an aqueous 
solution of KOH, vacuum filtered and allowed to dry overnight yielding compound 18d. The 
same synthetic procedure for dyes 19a-c was followed to synthesize compound 19d.       
3.3.6 Scheme of heptamethine quinoline-based cyanine dyes 
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3.3.7 The synthesis of heptamethine quinoline-based cyanine dyes 
The synthetic procedures for the bis-aldehyde linkers 20a-b were done using the 
procedures proposed by the Henary lab. First, a solution of DMF dissolved in DCM was allowed 
to cool to 0 °C. POCl3 was then added to the solution dropwise over a course of 30 min. 
cyclohexone (20a) or t-butyl cyclohexone (20b) was added dropwise over a course 15 min, while 
the temperature was maintained at 0 °C. The reaction mixture was allowed to stir for 15 min then 
refluxed for 4 h. The reaction mixture was poured over ice and remained in the aqueous solution 
for 12 h, affording a yellow precipitate (21a-b). The linkers were used without further 
purification.  
The heterocyclic salts previously used (17a and 13) were utilized again for the 
heptamethine cyanine dye series. 2-methyl quinoline (16) and 4-methyl quinoline (24) was 
reacted with ethyl iodide and methyl iodide, respectively. The reaction mixture was dissolved in 
acetonitrile and heated to 100 °C for 12 h. The reaction was allowed to cool and poured into an 
excess of ethyl ether yielding a crude yellow precipitate which was then collected using vacuum 
filtration. The ethyl alkylated heterocyclic salt (22) and methyl alkulated heterocyclic salt (25) 
was used without further purification.  
 The heptamethine quinoline-based cyanine dye synthetic procedure is new but followed 
similar procedures previously used in the synthesis of squarine dyes. 1 molar equivalence of 
heterocyclic salts (17a, 22, 13 and 25) was added to a 1 molar equivalence of vilsmier linkers 
(21a-b) and dissolved in a 7:3 volumetric equivalence of toluene and butanol. The reaction vessel 
was equipped with a Dean-Stark apparatus filled with toluene and condenser. The reaction 
mixture was heated to 130 °C for 4 h. Another 1 molar equivalence of the same salts and a 2 
molar equivalence pyridine was added to the reaction mixture and heated for another 3 h. The 
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reaction was monitored under UV-Vis spectroscopy.  Upon completion, the reaction mixture was 
allowed to cool and added to an excess of ethyl ether yielding the crude precipitate which was 
collected using vacuum filtration. The crude compound was recrystallized using ethanol and 
washed with water, acetone, and methanol yielding pure compounds 23a-f and 24a-b.   
 
3.3.8 Characterization  
6-fluoro-2-((1E,3E)-5-((E)-6-fluoro-1-methylquinolin-2(1H)-ylidene)penta-1,3-dien-1-yl)-1-
methylquinolin-1-ium iodide, 14a; Yield 69%; mp: > 260 °C; 1H NMR (400 MHz, DMSO)  4.01 
(s, 6 H), 6.30 (d, J = 12 Hz, 2 H), 7.23 (m, 2 H), 7.78 (dd, 2 H), 7.80 (t, 1 H), 7.98 (d, J = 9.2 Hz 
2 H), 8.08 (dd, 2 H), 8.17 (d, J = 9.2 Hz 2 H), 8.31 (d, J = 12.8 Hz 2 H); 19F NMR (376 MHz, 
DMSO/HFB)  163.46.  
2-((1E,3Z)-3-bromo-5-((E)-6-fluoro-1-methylquinolin-2(1H)-ylidene)penta-1,3-dien-1-yl)-6-
fluoro-1-methylquinolin-1-ium iodide, 14b, Yield 22%; mp: > 260 °C; 1H NMR (400 MHz, 
DMSO)  3.98 (s, 6 H), 6.27 (d, J = 12.8 Hz, 2 H), 7.69 (m, 2 H), 7.77 (dd, 2 H), 7.96 (d, J = 9.6 
Hz, 2 H), 8.05 (dd, 2 H), 8.14 (d, J = 9.6 Hz, 2 H), 8.28 (d, J = 12.8 Hz, 2 H) ); 19F NMR (376 
MHz, DMSO/HFB)  162.91.  
2-((1E,3Z)-3-chloro-5-((E)-6-fluoro-1-methylquinolin-2(1H)-ylidene)penta-1,3-dien-1-yl)-6-
fluoro-1-methylquinolin-1-ium iodide, 14c, Yield 75%; mp: > 260 °C; 1H NMR (400 MHz, 
DMSO)  4.00 (s, 6 H), 6.32 (d, J = 13.2 Hz, 2 H), 7.71 (m, 2 H), 7.79 (dd, 2 H), 7.96 (d, J = 9.6 
Hz, 2 H), 8.07 (dd, 2 H), 8.19 (m, 2 H); 19F NMR (376 MHz, DMSO/HFB)  163.01.  
2-((1E,3Z)-3-(4-bromophenyl)-5-((E)-6-fluoro-1-methylquinolin-2(1H)-ylidene)penta-1,3-dien-
1-yl)-6-fluoro-1-methylquinolin-1-ium iodide, 15a, Yield 65%; mp: > 260 °C; 1H NMR (400 
MHz, DMSO)  3.71 (s, 6 H), 5.86 (d, J = 14 Hz, 2 H), 7.36 (d, J = 8.4 Hz, 2 H), 7.63 (d, J = 3.2 
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Hz, 2 H), 7.67 (m, 4 H), 7.75 (m, 2 H), 7.93 (dd, 2 H), 8.06 (m, 4 H), 8.20 (d, J = 14 Hz, 2 H);  19F 
NMR (376 MHz, DMSO/HFB)  162.88. 
6-fluoro-2-((1E,3Z)-5-((E)-6-fluoro-1-methylquinolin-2(1H)-ylidene)-3-(4-
(trifluoromethyl)phenyl)penta-1,3-dien-1-yl)-1-methylquinolin-1-ium iodide, 15b, Yield 42%; 
mp: > 260 °C; 1H NMR (400 MHz, DMSO)  3.68 (s, 6 H), 5.82 (d, J = 13.6 Hz, 2 H), 7.59 (dd, 
2 H), 7.64 (dd, 2 H), 7.79 (m, 4 H), 7.91 (s, 4 H), 8.22 (d, J = 14 Hz, 2 H); 19F NMR (376 MHz, 
DMSO/HFB)  162.84, 162.78. 
2-((1E,3Z)-3-chloro-5-((E)-6-fluoro-1-methylquinolin-2(1H)-ylidene)penta-1,3-dien-1-yl)-6-
fluoro-1-methylquinolin-1-ium iodide, 14c, Yield 65%; mp: > 260 °C; 1H NMR (400 MHz, 
DMSO)  3.98 (s, 6 H), 6.29 (d, J = 12.8 Hz, 2 H), 7.73 (m, 2 H), 7.77 (dd, 2 H), 7.99 (d, J = 9.6 
Hz, 2 H), 8.15 (dd, 2 H), 8.19 (d, J = 9.6 Hz, 2 H), 8.32 (d, J = 12.8 Hz, 2 H) ); 19F NMR (376 
MHz, DMSO/HFB)  163.91.  
2-((1E,3Z)-3-chloro-5-((E)-1-methylquinolin-2(1H)-ylidene)penta-1,3-dien-1-yl)-1-
methylquinolin-1-ium iodide, 17a, yield 70%, mp: 218-220 °C; 1H NMR (400 MHz, DMSO)  
3.98 (s, 6 H), 6.32 (d, J = 14.8 Hz, 2 H), 7.53 (t, J = 8 Hz, 2 H), 7.81 (t, J = 7.2 Hz, 2 H), 7.91 ( 
dd, 4 H), 8.00 ( d, J = 8 Hz, 2 H), 8.21 (dd, 4 H). 
2-((1E,3Z)-3-chloro-5-((E)-1-methylquinolin-2(1H)-ylidene)penta-1,3-dien-1-yl)-1-
methylquinolin-1-ium 4-methylbenzenesulfonate, 17b, yield 67%, mp: 219-221 °C; 1H NMR 
(400 MHz, DMSO)  2.29 (s, 3 H), 3.99 (s, 6 H), 6.30 ( d, J = 12.8 Hz, 2 H), 7.11 (d, J = 7.6 Hz, 
2 H), 7.493 (dd, 4 H), 7.84 (m, 8 H), 7.99 (dd,  4 H). 
2-((1E,3Z)-3-chloro-5-((E)-1-methylquinolin-2(1H)-ylidene)penta-1,3-dien-1-yl)-1-
methylquinolin-1-ium methyl sulfate, 17c, yield 66%, mp: 217-219 °C; 1H NMR (400 MHz, 
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DMSO)  3.38 (s, 3 H), 4.00 (s, 6 H), 6.32 (d, J = 13.2 Hz, 2 H), 7.51 (t, J = 7.2 Hz, 2 H), 7.79 (t, 
J = 13.2 Hz, 2 H), 7.89 (dd, 4 H), 7.92 ( d, 2 H), 8.01 (dd, 4 H).  
2-((1E,3Z)-3-chloro-5-((E)-1-methylquinolin-2(1H)-ylidene)penta-1,3-dien-1-yl)-1-
methylquinolin-1-ium chloride, 17d, yield 58%, mp: 218-219 °C; 1H NMR (400 MHz, DMSO)  
4.01 (s, 6 H), 6.33 (d, J = 14.8 Hz, 2 H), 7.54 (t, J = 8 Hz, 2 H), 7.82 (t, J = 7.2 Hz, 2 H), 7.92 ( 
dd, 4 H), 8.03 ( d, J = 8 Hz, 2 H), 8.21 (dd, 4 H). 
4-((E)-2-((E)-2-chloro-3-(2-((Z)-1-methylquinolin-4(1H)-ylidene) ethylidene)cyclohex-1-en-1-
yl)vinyl)-1-methylquinolin-1-ium iodide, 24a, yields 75%, mp: >220 °C; 1H NMR (400 MHz, 
DMSO)  1.86 (t, J = , 2 H), 2.78 (t, J =, 4 H), 3.94 (s, 6 H), 6.94 (d, J =, 2 H), 7.30 (d, J =, 2 H), 
7.57 (t, J = , 2 H), 7.80 (m, 4 H), 7.96 (d, J =, 2 H), 8.03 (d, J =, 2 H), 8.42 (d, J =, 2 H); HRMS 
(ESI) m/z: calcd. for C30H28ClN2
+ 451.1925, obsd 451.1946.  
4-((E)-2-((E)-5-(tert-butyl)-2-chloro-3-(2-((Z)-1-methylquinolin-4(1H)-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1-methylquinolin-1-ium iodide, 24b, yields 77%, 
mp: >220 °C; 1H NMR (400 MHz, DMSO)  1.11 (s, 9 H), 1.50 (t, 1 H), 2.24 (t, J = , 2 H), 3.05 
(d, 4 H), 4.00 (s, 6 H), 7.03 (d, J =, 2 H), 7.36 (d, J =, 2 H), 7.63 (t, J = , 2 H), 7.84 (m, 4 H), 8.00 
(d, J =, 2 H), 8.03 (d, J =, 2 H), 8.53 (d, J =, 2 H); HRMS (ESI) m/z: calcd. for C34H36ClN2
+ 
508.1255 obsd 254.1307 Z=2.  
2-((E)-2-((E)-2-chloro-3-(2-((E)-1-methylquinolin-2(1H)-ylidene)ethylidene)cyclohex-1-en-1-
yl)vinyl)-1-methylquinolin-1-ium iodide, 23a, yields 72%, mp: >220 °C; 1H NMR (400 MHz, 
DMSO)  1.86 (t, J = , 2 H), 2.78 (t, J =, 4 H), 3.94 (s, 6 H), 6.31 (d, J =, 2 H), 7.45 (t, J =, 2 H), 
7.74 (t, J = , 2 H), 7.88 (m, 6 H), 8.03 (m, 4 H) HRMS (ESI) m/z: calcd. for C30H28ClN2
+ 452.0175, 
obsd 452.1949.  
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2-((E)-2-((E)-5-(tert-butyl)-2-chloro-3-(2-((E)-1-methylquinolin-2(1H)-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1-methylquinolin-1-ium iodide 23b, yields 77%, 
mp: >220 °C; 1H NMR (400 MHz, DMSO)  1.11 (s, 9 H), 1.50 (t, 1 H), 2.24 (t, J = , 2 H), 3.05 
(d, 4 H), 4.00 (s, 6 H), 7.03 (d, J =, 2 H), 7.36 (d, J =, 2 H), 7.63 (t, J = , 2 H), 7.84 (m, 4 H), 8.00 
(d, J =, 2 H), 8.03 (d, J =, 2 H), 8.53 (d, J =, 2 H); HRMS (ESI) m/z: calcd. for C34H36ClN2
+ 
508.1255 obsd 254.1306 (z=2).  
2-((E)-2-((E)-2-chloro-3-(2-((E)-1-ethylquinolin-2(1H)-ylidene)ethylidene)cyclohex-1-en-1-
yl)vinyl)-1-ethylquinolin-1-ium iodide, 23c, yields 66%, mp: >220 °C; 1H NMR (400 MHz, 
DMSO)  1.06 (t, J = , 6 H), 1.83 (t, 2 H) 2.63 (m, 4 H), 4.37 (m, 4 H), 6.24 (d, J =, 2 H), 7.45 (t, 
J =, 2 H), 7.85 (t, J =, 2 H), 7.89 (m, 6 H), 8.03 (d, J =, 2 H), 8.11 (d, J =, 2 H); HRMS (ESI) m/z: 
calcd. for C32H32ClN2
+ 480.0715 obsd 479.2234.  
2-((E)-2-((E)-5-(tert-butyl)-2-chloro-3-(2-((E)-1-ethylquinolin-2(1H)-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-1-ethylquinolin-1-ium iodide, 23d, yields 67%, mp: 
>220 °C; 1H NMR (400 MHz, DMSO)  1.08 (s, 9H), 1.41 (t, 6 H), 1.44 (t, 1 H), 2.22 (t, J = , 2 
H), 2.91 (d, 2 H), 4.56 (m, 4  H), 6.28 (d, J =, 2 H), 7.46 (t, J =, 2 H), 7.61 (t, J =, 2 H), 7.91 (m, 6 
H), 8.05 (m, 4 H); HRMS (ESI) m/z: calcd. for C36H40ClN2
+ 536.1795 obsd 268.1462 (z=2).  
2-((E)-2-((E)-2-chloro-3-(2-((E)-6-fluoro-1-methylquinolin-2(1H)-ylidene)ethylidene)cyclohex-
1-en-1-yl)vinyl)-6-fluoro-1-methylquinolin-1-ium iodide  23e, yields 55%, mp: >220 °C; 1H NMR 
(400 MHz, DMSO)  1.86 (br, 2 H), 2.69 (br, 4 H), 3.91 (s, 6 H), 6.24 (d, J =, 2 H), 7.58 (t, J =, 2 
H), 7.70 (d, J =, 2 H), 7.95 (m, 8 H); 19F NMR (376 MHz, DMSO/HFB)  116.84. 
2-((E)-2-((E)-5-(tert-butyl)-2-chloro-3-(2-((E)-6-fluoro-1-methylquinolin-2(1H)-
ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-6-fluoro-1-methylquinolin-1-ium iodide 23f, yields 
55%, mp: >220 °C; 1H NMR (400 MHz, DMSO)  1.08 (s, 9 H), 1.49 (br, 1 H), 2.91 (br, 2 H), 
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3.92 (s, 6 H), 6.25 (d, J =, 2 H), 7.57 (br, 2 H), 7.70 (br, 2 H), 8.00 (m, 8 H) ); 19F NMR (376 MHz, 
DMSO/HFB)  162.77. 
3.3.9 Optical Properties  
Stock solutions of the dyes and standard were prepared by weighing the solid on a 5-digit 
analytical balance in an amber vial and adding solvent via a class A volumetric pipette to a final 
concentration of 1.0 mM. The vials were vortexed for 20 s and then sonicated for 15 min to ensure 
complete dissolution. The stock solutions were stored in a dark freezer at 4 °C when not in use. 
Working solutions were prepared just prior to use by dilution of the stock to final concentrations. 
Stock solutions were used to prepare six dilutions of dyes in ethanol and the standard with 
concentrations ranging from 1 μM to 4 μM using a class A volumetric pipette in order to maintain 
absorption between 0.1 and 1.0. The dye solutions were diluted ten-fold for fluorescence in order 
to minimize the inner filter effect. The absorbance spectra of each sample were measured in 
triplicate from 400nm to 900 nm. The emission spectrum of each sample was measured in triplicate 
with a 750 nm excitation wavelength.  
For molar absorptivity, the absorbance at the wavelength of maximum absorbance (λmax) was 
determined and the absorbance of each sample at λmax was plotted as a function of dye 
concentration. The linear regression equation was computed using Microsoft Excel. 
 
3.4 Results and Discussion 
3.4.1 Optical Properties  
 
Table 3.1: Absorbance data of the fluorinated quinoline-based pentamthine dyes 
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Dyes λabs (nm) ε (L·mol−1  · cm−1) 
14a 718 161,000 
14b 701 188,000 
14c 703 191,000 
15a 709 110.000 
15b 711 111,000 
15c 709 222,000 
 
Quinoline based pentamethine cyanine dyes absorb at 715 nm with a molar absorptivity 
value of 141,000 (L · mol−1 · cm−1) [14]. Upon introduction of fluorine to the heterocycle, a 100 
nm increase to the absorbance wavelength and an increase of 20,000 (L · mol−1 · cm−1) to the 
molar absorptivity was observed. The introduction of a bromine and chlorine atom to the central 
carbon of the polymethine bridge, to the fluorine-substituted quinoline-based pentamethine 
cyanine dyes,  decreased the absorbance value by 19 nm and 15 nm, respectively; however, 
increases the molar absorptivity by 26,000 (L · mol−1 · cm−1) and 30,000 (L · mol−1 · cm−1), 
respectively. Phenyl bromide and phenyl chloride substituents incorporated to the polymethine 
bridge has little variance in comparison to each other, but with respect to the unsubstituted 
straight chain linker 14a, observed a 9 nm and 7 nm decreases to absorbance values, as well as a 
51,000 (L · mol−1 · cm−1) and 50,000 (L · mol−1 · cm−1) decrease to the molar absorptivity, 
respectively. Unsuspectedly, however, the introduction of (trifluoromethyl) benzene increased 
the molar absorptivity by 61,000 (L · mol−1 · cm−1) in comparison to 14a. This could be due to 
the decreased aggregation of the compounds due to three fluorine atoms, along with increase 
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electron withdrawing ability of the fluorine atoms from the phenyl ring, leading it to donate even 
more electrons to polymethine bridge.  
 
 
Table 3.2 Absorbance data of the quinoline-based heptamthine dyes 
 
Dyes λabs (nm) ε (L · mol−1 · cm−1) 
24a 953 119,000 
24b 954 133,000 
23a 847 111,000 
23b 849 170,000 
23c 851 215,000 
23d 855 217,000 
23e 856 100,000 
23f 859 125,000 
 
Quinoline based cyanine dyes observe 100 nm shift based on the position of the methyl 
group of the heterocycle. 4-methyl quinoline dyes have absorbance values approximately 100 nm 
more (redshifted) versus the dyes that contain 2-methyl quinoline heterocycles due to the extra 
double bond adding to the conjugation. Compounds 63 and 64 both incorporated the 4-methyl 
quinoline heterocycles and had absorbance values in the 953 and 954 nm range. The addition of 
the t-butyl group to the bisaldehyde vilsmier heptamethine linker increases the absorbance by 1-2 
nm throughout the series of dyes. Compounds with 2-methyl quinoline that contained a methyl 
substituent of the nitrogen atom of the heterocycle absorbed at 847 nm, increasing the methyl to 
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an ethyl increased the absorbance to 851 nm. Again the introduction of the fluorine substituent 
redshifted the absorbance to 859 nm. Molar absorptivity was enhanced upon the introduction of 
the t-butyl group by 14,000 (L · mol−1 · cm−1), 59,000 (L · mol−1 · cm−1), 2,000 (L · mol−1 · 
cm−1), and 25,000 (L · mol−1 · cm−1) for the 4-methyl quinoline, 2-methyl quinoline with methyl 
substituent off the nitrogen of the heterocycle, 2-methyl quinoline with ethyl substituent off the 
nitrogen of the heterocycle, and the fluorinated compound, respectively. With respect to the 
compounds without the t-butyl group, compound (ethyl) observed a significantly higher 
absorptivity in comparison to the 4-methyl quinoline, 2-methyl quinoline with the methyl group, 
and the fluorinated series. This trend is parallel with previously synthesized series. 
 
3.4.2 Photodynamic therapy data 
Photodynamic therapy (PDT) preliminary data determines the degree of reactive oxygen 
species generation and ultimately the effectiveness of certain contrast agents for the application 
by using plasmid DNA in solution with the contrast agent. The data results determine multiple 
aspects of the dye, laser, and solution. To determine if the contrast agent alone is cytotoxic, 
which is an undesirable results; the dye is introduced to the DNA without a laser radiation 
(“dark” slots). The absence of laser prevents the dye from going into the excited state and 
prevents the dye from ROS generation. The other control groups are the laser without the dye to 
determine that the laser is not inducing the DNA damage (control light: not seen in the diagram), 
and finally, control dark state to assure that the buffer solution is not damaging DNA (“control 
dark” slot). Testing the effectivity of the compounds is determined by quantifying the degree of 
cleavage of the plasmid DNA. The two types of cleavage observed is linear cleavage (blot with 
largest RF) where the plasmid DNA is completely cleaved and nicked where the one strand is 
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nicked. Although linear cleavage is more effective, the accumulation of enough nicked DNA 
(middle plot) is sufficient in leading the cells to apoptosis. 
A few of the fluorinated quinoline-based pentamethine dyes with varying linkers that is 
substituted at the central carbon with bromine, bromobenzene, and trifluoro methyl benzene were 
tested for their ability to cleave plasmid DNA.   
 
Figure 3.1 PDT gel image (FM-21=14b; FM 29=15a). 38 µM b.p of pUC19 plasmid, 25 
µM  dye, 30 min irradiation 638 nm. CMH-41 was syneyhsized by Cory Holder (see: Holder 
thesis) Data Obtained by Dr. Grant’s laboratory 
 
 
 
 
Figure 3.2 PDT gel image of 15c with varying concentrations. Data obtained by Dr. 
Grant’s laboratory. 
 
 
The varying counter-ions pentamethine dyes were tested as well. Cuvette samples of 
bromine (14b) in comparison to bromobenzene (15a) show that the bromide substituent is more 
effective with a greater deal of nicked cleavage. The trifluoro methyl benzene (15c) results 
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indicated that the compound yielded insufficient DNA cleavage. The dyes with differing 
counter-ions continuously showed the chloride counter-ion (19d) is most effective that iodide 
which is more effective than the organic counter-ions (19b-c). This demonstrates the versatility 
of cyanine dyes due to their multiple sites of modifications, which allows for optimization for the 
respected application.   
 
 
 
3.5 Conclusion 
The quinoline heterocycle has proven to be an effective addition to the cyanine dyes scaffold 
due to the effects it has on the optical properties. The structure of the heterocycle contributes an 
extra double bond to the conjugation of the dye yielding a further red-shifted compound. The 
lack fluoresces enables it to be used in PDT application. The versatility of the dyes enables the 
addition of substituents to multiple locations on the dye which allows for the synthesis of 
multiple derivatives and tailoring for the desired use. Here the focus was to introduce a fluorine 
atom into the heterocycle for PDT application due to the pharmacological benefits fluorine has 
had in previous research. Next, the effects of iodide, a common counter-ion of cyanine dyes, was 
studied due to the triplet state quenching it provides. This quenching is an undesirable factor for 
PDT 
Figure 3.3 PDT gel image for the iodine counterion (17a) and chlorine 
counterion (19d). Data Obtained by Dr. Grant’s Lab (Kanchan). 
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application, and due to the modifiability of cyanine dyes, this was overcome by the use of 
different alkylating agents and synthetic procedures. Finally, the quinoline heterocycle was 
introduced to the heptamethine dyes allowing the dyes to be far red-shifted into the NIR II region 
which a hugely untapped field for cyanine dyes. The compounds were studied for the optical 
properties and some were tested for their effectivity in PDT application, proving that the fluorine 
atom slightly enhances DNA cleavage while the chloride counter-ion enhances the cleavage in 
comparison to the common iodide.               
 
 
 
 
 
4 RESEARCH OVERVIEW  
My research entails the design and the synthesis of biologically relevant cyanine dyes. 
Cyanine dyes are a class of near-infrared (NIR) contrast agents that have shown great potential in 
medical application. These dyes are versatile and modifiable allowing for specific tailoring and 
optimization sites; as well as, absorb light at a longer wavelength which is both safer and optimal 
for contrast due to the low absorption of endogenous tissue in NIR spectral region. The projects 
that I have taken on include synthesis of photosynthesizing agents for photodynamic therapy 
(PDT), synthesis of contrast agents for optoacoustic imaging modalities (OAI), and the design 
and execution of an optimized procedure for the synthesis of highly hydrophobic fluorescent 
compounds for human serum albumin (HSA) studies. 
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 As a medicinal organic chemist both synthetic and biological theories must be utilized in 
order to yield compounds with medicinal relevancy. Tailoring weakly fluorescent 
photosynthesizing agents that, upon NIR laser excitation, interact with singlet oxygen and 
undergo intersystem crossing into the triplet state is ideal for PDT application. This quantum 
phenomenon leads to the generation of reactive oxygen species (ROS) which ultimately leads the 
cell to an apoptotic state. PDT utilizes these agents as guidance systems for cancer therapy. 
Although PDT currently uses alternative contrast agents (such as porphyrins), in comparison to 
cyanine dyes, these are unfavorable due to synthetic and solubility issues, shorter wavelength 
absorption reducing the penetration depth, and poor clearance leading to major side effects and 
poorer quality of life. The dyes I currently synthesize are as effective and improve on these 
factors. I aim to further optimize these compounds for PDT application in the field of cancer 
therapeutics.   
Molecular imaging (MI) facilitates early detection of disease which has proven to be 
among the most effective ways of treating cancers. There are various studies which have shown 
much correlation relating survival rate to early-stage detection. OAI is a new and innovative MI 
technique that incorporates contrast agents with ultrasound imaging technology. Upon the 
introduction of the NIR contrast agent and NIR light, the dye goes into an excited state where it 
observes various relaxation pathways to the ground state. Among those pathways, dyes that 
exhibit high levels of vibration relaxation induces molecular thermal expansion leading to an 
acoustic signal generation which is detectable by ultrasound sensors. Once again NIR contrast 
agents enhance this imaging modality by providing better signal generation that acts as a 
targeting tool; while they too are enhanced by increasing their depth penetration in comparison to 
their fluorescence signal. Some cyanine dyes have been tested and proven to be effective; 
75 
however, are far from optimal. Due to the novelty of this technique, not much is known for of 
what constitutes as optimal characteristics for the contrast agents. Herein I systemically aim to 
further develop a large library of compounds for screening to better understand and optimize 
OAI techniques.    
HSA is the most abundant blood protein in the human body and plays a crucial role in the 
delivery of various molecules. It has been well established that the protein contains four 
hydrophobic binding pockets, which led to my design of hydrophobic contrast agents. Here I 
aimed to better understand the hindrances and binding properties of HSA which than can be used 
in coherence with other studies. Along with the design of the compounds, I successfully optimize 
the synthetic procedure for these compound, allowing for an alternative synthetic method that 
resulted in superior yields and allowed for an easier purification method.  
             
76 
APPENDICES  
Appendix Chapter 2 
Table of content: 
1H and 13C NMR spectra of all cyanines synthesized in this study  
Absorbance, fluorescence spectra and Beer-Lambert plots of all cyanines synthesized in 
this study 
 
1H and 13C NMR spectra of all cyanines synthesized in this study 
 
*30f-30j correspond to 6a-e and were synthesized by Dr. Andrew Levitz (See: Levitz dissertation) 
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Absorbance, fluorescence spectra and Beer-Lambert plots of all cyanines synthesized in 
this study 
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FM_63_ESIPOS_HENARY_041918 #162-172 RT: 2.30-2.44 AV: 11 NL: 1.12E6
T: FTMS + p ESI Full ms [50.00-1000.00]
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FM_61_ESIPOS_HENARY_041918 #163-171 RT: 2.29-2.40 AV: 9 NL: 7.47E7
T: FTMS + p ESI Full ms [50.00-1000.00]
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FM_62_ESIPOS_HENARY_041918 #145-149 RT: 2.06-2.11 AV: 5 NL: 2.61E5
T: FTMS + p ESI Full ms [50.00-1000.00]
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FM_60_ESIPOS_HENARY_041918 #145-149 RT: 2.04-2.10 AV: 5 NL: 7.32E7
T: FTMS + p ESI Full ms [50.00-1000.00]
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FM_65_ESIPOS_HENARY_041918 #139-145 RT: 1.96-2.04 AV: 7 NL: 2.14E7
T: FTMS + p ESI Full ms [50.00-1000.00]
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FM_64_ESIPOS_HENARY_041918 #144-155 RT: 2.03-2.18 AV: 12 NL: 4.97E7
T: FTMS + p ESI Full ms [50.00-1000.00]
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